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Summary 
Background 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with severe long-
term impact on patients, their caregivers and on the society in general [1]. The 
treatment of PD is symptomatic.  Surgical treatment with chronic high frequency 
stimulation of the subthalamic nuclei (STN-DBS) has been shown to provide long 
term symptom relief with few complications in selected patients with PD [2-4].  
Aim 
The aim of the thesis has been to elucidate the long-term effects of STN-DBS on the 
development of clinical symptoms in PD. 
Materials and methods 
All PD patients treated with STN-DBS between 2001-2007 at Rikshospitalet (N=144) 
and at Stavanger University Hospital (N=28) were prospectively followed with 
standardized examinations, and all 172 STN-DBS operated PD patients were included 
in the scientific material for the thesis. As reference we used the patients from a 
population-based prevalence study conducted with patient recruitment between 
September 1992 and May 1993, before STN-DBS was available. 
Results  
We confirm that STN-DBS surgery can be performed with good and stable long time 
results on dopaminergic motor symptoms. Perioperative mortality was low and the rate 
of major adverse events low. The non-motor features of PD seem to develop 
independently of intervention with STN-DBS, as do FOG and falls. Fatigue is 
observed to develop at a high rate in STN-DBS operated patients after the first year 
postoperatively. 
Conclusions and implications 
STN-DBS is a very good treatment option for motor symptoms in selected patients 
with advanced PD. The benefits of the treatment are limited to motor symptom control 
as the underlying PD pathology continues to develop in operated patients similar to the 
natural history of PD. Fatigue seem to develop at a high rate in STN-DBS operated 
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patients after the first year postoperatively. Our findings are relevant to advising 
patients both about the indication for, and the timing of, STN-DBS surgery in PD 
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General introduction 
Deep brain stimulation has been available in Norway as a treatment option for PD for 
14 years [9]. The promising results from other centres abroad in the late 90-ies were 
giving new hope to PD patients suffering from severe motor symptoms, fluctuations 
and drug side effects. International techniques and protocols were adapted at 
Rikshospitalet, which was first in Norway to offer STN-DBS from 2001. There was a 
strong consensus among the staff involved at Rikshospitalet that the opportunity of 
following the STN-DBS patients prospectively should be pursued, and a standardised 
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set of examinations was established and documented in the medical records from the 
very beginning. Preoperative evaluations, peroperative procedures and postoperative 
follow-up were thus planned and conducted in a standardised fashion for all patients. 
As the Stavanger University Hospital introduced this novel treatment in 2006, similar 
principles were adapted. A national database for STN-DBS was discussed, and 
generally agreed on, but was never implemented. In 2009, the Department of Health 
decided to centralize this (and other) specialized treatment to two centres in Norway, 
in Oslo and in Trondheim. At that time, the treatment had been offered to Norwegian 
PD patients for 8 years, and there was a growing need to document the results for the 
patients. Tapping in to the prospectively registered patient information from medical 
records, and supplementing with extra follow-ups, we set out to elucidate the long 
term clinical effects after STN-DBS for our patients. From international literature it 
was increasingly clear that STN-DBS had great positive effects on dopaminergic 
motor symptoms in selected PD patients. Rapports indicated good effect over time, 
with long standing reduction of motor symptoms and reduced need for dopaminergic 
medication. But the patient materials behind much of the available literature were 
relatively small, follow-up time was short to medium long, and there was an ongoing 
debate on the effect of STN-DBS on other aspects of PD like the assumed non-
dopaminergic motor symptoms, non-motor symptoms and indeed whether or not STN-
DBS could modulate the disease progression itself. On this background it seemed 
called for to use the materials of prospectively followed-up patients available from 
Rikshospitalet and Stavanger University Hospital to confirm or examine the positive 
and lasting motor effects of STN-DBS, and to explore the effect on other clinical 
symptoms of PD over time after surgery. We also wanted to explore possible disease 
modulating effects on PD of STN-DBS, by looking at progression of cardinal 
symptoms after surgery and on cumulative postoperative mortality. The postulate of a  
potential neuroprotective effect of STN-DBS has been primarily driven by a 
theoretical concept related to an induction of reduced cytotoxic glutamate release in 
substantia nigra by the procedure which again leads to less neurodegeneration [10, 11]. 
Results from early animal studies also lent support to the neuroprotection hypothesis 
[12-14]. However, no controlled patient studies have provided data to support this 
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concept and it has therefore been seen as one of the major unanswered research issues 
related to the STN-DBS procedure [1].  
Motor symptoms that have poor or no response to dopaminergic treatment include 
axial motor involvement causing postural instability and gait difficulties (PIGD) [15, 
16], freezing of gait (FOG) and falls. Such symptoms have been shown to have large 
impact on the daily life of PD patients and for their caregivers [17, 18]. The symptoms 
increase in PD patients as the disease develops over time, corresponding to the 
increased number of dispersed lesions in the brain [19]. The PIGD pattern of 
parkinsonism is associated with a faster rate of cognitive decline and subsequently 
with an increased risk of dementia [19, 20]. The pathophysiology of PIGD, FOG and 
falls are likely to be complex, and is not fully understood. Locomotor areas in the 
brainstem and in the midbrain are believed to be important in the control of balance 
and gait, and exacerbation of cognitive deficits may also influence the progression of 
axial symptoms in PD [19]. Dopaminergic cell loss and reduced dopamine outflow are 
considered less important, leading to the assumption that STN-DBS should not have a 
major impact on the development of such symptoms, and that they should develop 
independently in operated patients similar to non-operated patients. This matches with 
the clinical experience that these symptoms are found to be disabling for patients both 
on dopaminergic medication and after STN-DBS treatment. However, a meta-analysis 
of a number of long term follow-up studies after STN-DBS and GPi-DBS (deep brain 
stimulation in the globus pallidus internus) has indicated acute, positive effects on 
PIGD symptoms [21].   
The progressing incapacitation experienced by PD patients is caused not only by 
increasing motor symptoms, on which STN-DBS has been shown to have positive 
effects, but also by a wide range of progressing non-motor symptoms.  Common non-
motor symptoms in PD include cognitive impairment, neuropsychiatric symptoms, 
sleep problems and autonomic symptoms. The characteristical progressive dopamine 
depletion in the nigrostriatal tract cannot directly explain such non-motor PD 
symptoms, and other brain areas and transmitter systems are assumed to also be 
affected by PD as these symptoms arise in PD patients. Abnormalities in several 
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neurotransmitter systems have been found in PD, including in the adrenergic, in the 
serotonergic and in the cholinergic [22] . Braak et al have advocated a sequential 
anatomical progression of PD, involving several areas of the brain [23, 24]. According 
to this theory PD (characterized pathologically by Lewy bodies and α-synuclein 
pathology) may start out in the brainstem and subsequently spread through the 
midbrain to mesocortex and finally neocortex. Based on the findings of pathological 
changes in the brain areas they suggest a staging of PD development from 1-6. The 
early stages (1 and 2) would be identified by inclusions in the medulla oblongata, 
pontine tegmentum and the olfactory bulb and anterior olfactory nucleus. Early 
involvement of olfactory structures could explain the early clinical finding of olfactory 
alterations in some PD patients, before the manifestation of hallmark motor symptoms 
[25]. It could also explain the early debut in some PD patients of sleep disorders, an 
important category of non-motor symptoms in PD [26] .  
As non-motor symptoms increase in severity during the natural development of PD, 
they often play a major role in the total disability of the patients with major impact on 
the need of care. Cognitive impairment and dementia have been shown to be major 
factors in decreased functioning in late stage PD [27, 28]. The risk of developing 
dementia is elevated in PD patients up to six times the risk in the general population 
with increasing risk with increasing age, and the resulting incidence of dementia 
amongst PD patients is approximately 10 % per year [29-31].  
Since non-motor symptoms in PD are believed to arise as the disease involves non-
dopaminergic areas of the brain, they would in principle not be expected to be affected 
by the electric stimulation in STN-DBS as this procedure is considered a dopaminergic 
treatment. It has been suggested that the surgical implantation of the electrodes could 
have lesioning effects, which in turn could also have non-motor effects. However, 
insufficient knowledge has been available on the development of non-motor symptoms 
in PD after STN-DBS, despite their major impact on the daily life of many late stage 
PD patients.  
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The early history of PD 
The history of Parkinson’s disease (PD) may be as old as the history of the human 
brain itself. But surprisingly, the disease seems to have gone unrecognised and 
unclassified up until modern time. It is unlikely that the reason is that PD arose as a 
disease only recently. The shorter average life spans in the past centuries may certainly 
have contributed to a lower prevalence of all diseases with onset late in life, including 
PD. But still it is somewhat surprising that PD was not recognised as a diagnose 
earlier. However, symptoms closely resembling parkinsonian cardinal symptoms are 
mentioned in ancient Egyptian texts, in ancient Hindu texts on traditional, Ayurvedic 
medicine and by the Greek physician Galen [32]. There have even been studies 
showing that traditional Ayurvedic herb treatments used for PD have positive effects 
on PD symptoms [33, 34].  In “Richard II” William Shakespeare lets the Duke of York 
suffer from “shaking, fumbling and palsy” – the text clearly describes a man with 
symptoms closely resembling PD [35]. Thus - small, probable imprints of PD on 
human life can be found way back in history. 
The modern history of PD 
The modern history of PD as a recognized disease entity is in general view thought to 
have begun with James Parkinson’s famous publication from 1817; “An Essay on the 
Shaking Palsy” [36], although several physicians in the 17th and 18th centuries had 
described, at least in part, the same symptoms [37].  
In his essay, Parkinson described 6 patients, three from his own medical practice and 
three individuals he had observed on the streets of London. The essay was a systematic 
description of the cardinal symptoms of the disease later to bear his name. Parkinson 
described the characteristic resting tremor as opposed to tremor with motion, he had 
noted abnormal posture and gait difficulties, the paralysis and apparent diminished 
muscle strength. He also described the progressive nature of the symptoms over time. 
He wrongly suspected that the origin of the symptoms might be lesions in the cervical 
spinal cord. As James Parkinson remains one of the great names in the history of 
neurology, it might be of some interest in this neurosurgical thesis to note that James 
Parkinson was in fact a surgeon, not a neurologist. His work also provided a clue to the 
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work of later pioneers in Parkinson surgery, by being the first to report temporary 
tremor relief in a PD patient (his Case 6) after an apoplectic seizure [36] – an 
important lead for those surgeons attempting corticotomies to treat tremor in PD over a 
century later [38]. 
Many early neurologists picked up on James Parkinson’s work, most notably Jean-
Martin Charcot who in addition to contributing to the clinical understanding of PD 
(including defining the three cardinal symptoms of tremor, rigidity and bradykinesia) 
also suggested the renaming of the disease in honour of James Parkinson [39]. 
The medical community came closer to understanding the pathophysiology of PD in 
the early 20th century, as Frederic Lewy in 1912 discovered the Lewy bodies [40] and 
when Konstantin Tretiakoff in his 1919 thesis described how he observed degeneration 
and cell loss in the substantia nigra in association with PD [41]. However, the 
biochemical mechanisms behind the pathophysiology in PD was first further 
elucidated when the Swedish Nobel Prize laureate Arvid Carlsson in 1957 published 
his work on dopamine’s role as neurotransmitter [42] and Oleh Hornykiewicz’s work 
on describing dopamine’s role in PD [43]. Dopamine had been known as a substance 
since 1911, but levodopa (L-dopa) was first used as a drug in the treatment of PD in 
1967 [44]. Based on the work of Georg Cotzias et al. from 1969 L-dopa quickly 
became the drug of choice for treating PD symptoms [45] . Until L-dopa the only 
pharmacological treatment for PD was anticholinergics, with limited effect and many 
side effects.    
Epidemiology of PD 
PD is one of the most common movement disorders known, matched only by the 
prevalence of essential tremor [46]. It affects both women and men and the gender 
distribution is near equal, tough some studies have reported slightly higher prevalence 
in males [47]. The general prevalence of PD in Norway is about 100-150 patients per 
100.000 [48]. Incidence rates vary between studies but seems to be between 8.6 and 
19.0 per 100.000 in western countries. Worldwide, about 4 million people are 
estimated to suffer from PD. The incidence of PD increases with age, and accordingly 
the prevalence of PD is higher in demographically older populations. Thus, the 
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prevalence of PD is much higher in developed countries as compared to developing 
countries because of the much younger population in the developing countries. The 
prevalence of PD in people over 65 years is approximately 1-2 %, more than doubling 
up to a prevalence of 3-5 % in people over 85 years [49]. If PD symptoms occurs 
before age 50, it is denominated as “early onset”. This is the case in approximately 4 
% of PD patients [50].  
The impact on the society is high, both in direct and indirect cost - but also in the way 
PD affects the quality of life for many people suffering from PD and for their families. 
 
Pathogenesis 
The development of PD is characterised by progressive loss of dopaminergic neurons 
containing neuro-melanin. The pathogenic causes behind the cell loss are unknown. 
Possible mechanisms leading to progressive cell loss have been proposed to involve 
genetic and/or environmental factors: abnormal protein processing involving 
dysfunction of the ubiquitin-proteasome system, oxidative stress by free radicals, 
mitochondrial dysfunction, apoptosis, excitotoxity as well as inflammation [51]. The 
characteristical cell loss in PD takes place foremost in the pars compacta of the 
substantia nigra. Due to compensatory mechanisms both presynaptic (increased 
turnover of dopamine) and postsynaptic (increased dopamine receptor sensitivity), 
symptoms of PD do not develop in patients in the early stages of pathological cell loss 
[52]. Clinically, the symptoms of PD arise as the striatal dopamine levels drop beyond 
40-20 % of the normal levels and cell loss in the substantia nigra exceeds 50 % [53-
55]. The time over which the cell loss progresses before clinical onset of PD is 
unknown and may vary between individuals [56, 57]. The loss of dopaminergic, 
neuro-melanin containing neurons in the substantia nigra combined with the presence 
of Lewy bodies, has classically been regarded as the neuropathological and 
neurochemical hallmarks of PD. Lewy bodies are eosinophilic hyaline inclusions in 
the cytoplasm of neurons. α-synuclein has been shown to be a central component in 
Lewy bodies [58]. Lewy bodies are present in surviving neurons of the substantia nigra 
pars compacta in patients with clinical PD [59]. But Lewy bodies are also found in 
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other brain areas that also demonstrate cell loss in PD, as well as in the brains of 
patients with other neurodegenerative diseases. Thus, Lewy bodies may represent a 
common intracellular feature in some types of neuronal degeneration.  
In addition to atrophy of the substantia nigra, cell loss in PD is observed in the cortex, 
the prefrontal region, in the hypothalamus, the raphe nuclei, in sympathetic ganglia, in 
locus coeruleus, in the dorsal nuclei of the vagus, in the ventral tegmental area and in 
the nucleus basalis of Meynert [60, 61]. The finding of widespread cell loss in the 
brain in PD add to the increasing evidence for involvement in the clinical progression 
in PD of other pathways than the dopaminergic. Cholinergic, glutamatergic, 
noradrenergic and serotonergic signal systems have all been shown to be affected in 
PD patients [22]. Although the classical, cardinal motor symptoms of PD correspond 
well to impairment of dopaminergic signal pathways, other motor symptoms and non-
motor symptoms in PD may well develop by  progressively involving other non-
dopaminergic signal pathways [62]. 
 
Genetics and environmental factors in PD 
The risk of PD increases if a close family member develops the disease, by a factor of 
3 to 4 as compared to the general risk. And some families have had a history of PD 
affecting family members over generations. Thus, it has long been suspected that 
genetic factors play a major role in the pathogenesis of PD in many patients. An 
important discovery was made in 1997, after studying an Italian family with 
dominantly inherited early-onset parkinsonism. A mutation (Ala53Thr) on the long 
arm of chromosome 4, coding for α-synuclein, was found in the affected family 
members [63]. Later, this and several other mutations associated with the development 
of parkinsonism were identified at the same locus on chromosome 4, and the locus was 
subsequently named PARK1 [64]. An increasing number of mutations and loci has 
later been discovered [65, 66]. Known mutations can explain the development of 
parkinsonism in a minority of cases, and environmental causes may well be as 
important in the development of PD. The role of genetics in PD needs further research 
and elucidation, with the long-term goal of finding new treatment options. For now, 
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gene therapy for PD seems still far to come. Too little is known about exposition 
factors increasing the PD risk in the population. A large number of possible factors 
have been explored. Exposure to pesticides, living in rural areas and long-term 
consumption of well water have shown a moderately increased risk in a meta-analysis 
[67]. Interestingly, life style factors like smoking and coffee appears associated with 
reduced risk for developing PD – as opposed to the huge, negative impact smoking has 
on cardiovascular risk [68]. 
 
Pathophysiology 
Although the classical model of linear signal pathways in the basal ganglia used earlier 
to explain the pathophysiology in PD is far too simple [69], it still can be used to 
understand the basic pathophysiological mechanisms which allow STN-DBS to 
provide dopaminergic motor symptom control. The classical model suggest that the 
dopaminergic motor symptoms in PD are caused by nigrostriatal dopamine deficiency 
in the putamen leading to reduced inhibition of the STN, which in turn increases 
inhibitory outflow from the STN leading to increased inhibition of thalamocortical 
pathways supressing movement. DBS with STN as a target would then create a 
functional lesion, reducing inhibitory outflow from the STN thus alleviating motor 
symptoms. 
 
Motor symptoms 
Parkinsonism is defined as two or more of the four cardinal motor signs; resting 
tremor, muscular rigidity, bradykinesia and postural abnormalities [70].  
The most frequently occurring of these is bradykinesia, in many patients severely 
impairing activities of daily life (ADL). Bradykinesia also causes the common 
reduction of facial expression many PD patients experience, and the typical reduction 
in arm swing when walking.  
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Tremor is not present in all patients, but up to 70-80% of PD patients have resting 
tremor in the early disease stages [71]. Resting tremor in the arm and hand with a 
typical frequency of 4-6 Hz has been named “pill rolling tremor”, and has arguably 
become the symptom foremost associated with PD in the general public.  Tremor in 
the neck or lower limbs can occur, but is less frequent.  
Rigidity is a very disabling symptom, and many PD patients will put it on top of the 
list of features of PD impairing ADL. Severe rigidity also can cause pain, and many 
patients will opt to suffer considerable side-effects from drug treatments rather than 
reverting to a situation in which the prominent PD symptom is severe rigidity.  
Postural abnormality as a cardinal symptom in PD, really describes a number of 
postural changes including abnormal postures in the extremities, in the neck and in the 
trunk – often associated with rigidity. Abnormal postures can occur early in the course 
of PD, whereas real postural instability caused by impaired postural reflexes is more 
common in late stage PD. 
Other motor symptoms in PD includes motor symptoms thought to be secondary to the 
cardinal motor symptoms like dysarthria, hypophonia, dysphagia and sialorrhoea. 
Motor symptoms thought to be caused by impairment of other signal pathways than 
the dopaminergic, i.e. non-dopaminergic motor symptoms, include freezing of gait 
(FOG) and recurring falls. When postural instability and gait impairment dominates, 
the PD phenotype is known as the PIGD phenotype of PD (postural instability and gait 
disorder) – a phenotype in which non-dopaminergic motor symptoms may cause 
severe disability for the PD patient. 
 
Non-motor symptoms 
PD patients are likely to develop a wide range of symptoms which do not primarily 
arise from impaired motor function. Non-motor symptoms in PD include 
neuropsychiatric symptoms, sleep disorders, sensory symptoms, gastrointestinal 
symptoms and autonomic symptoms. Recently, fatigue has drawn increased attention 
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as a non-motor symptom common in advanced PD with a large impact on ADL 
function level in the individual patient. 
Neuropsychiatric symptoms in PD commonly progress during the course of PD, and 
include depression, apathy, hallucinations, cognitive dysfunction and dementia. 
Depression in PD may severely reduce the PD patient’s quality of life [72]. 
Development of cognitive impairment and dementia affect both the PD patients and 
caregivers, and may rapidly increase the caregiver’s burden of care. In the long term, 
up to 80% of PD patients may develop dementia [73, 74]. 
Autonomic symptoms can manifest in PD patients as bladder disturbances, changes in 
sweating or orthostatic hypotension. 
Sensory symptoms commonly occur in PD, and an early symptom of PD may be 
olfactory sensory disturbances.  Some PD patients suffer from centrally originating 
pain which may be difficult to alleviate effectively.  Visual dysfunction may also arise. 
Common gastrointestinal symptoms are constipation, excess salivation (dribbling) and 
dysphagia. 
Sleep disorders can arise in many forms, spanning from insomnia to excessive daytime 
somnolence.  
 
Medical treatment for PD 
From the advent of dopaminergic treatment with L-Dopa in the late 60’ies, a wide 
range of drugs have been developed and made available for PD patients. Dopamine 
agonists, monoamine oxidase B (MOA-B) inhibitors, COMT-inhibitors and 
amantadine are all part of the neurologist’s present pharmacological toolbox. A 
commonly used medication strategy is to combine drugs in order to delay treatment 
with L-dopa. However, most PD patients will at some point need treatment with L-
dopa and most patients subsequently develop motor complications. At that point the 
option of surgical treatment can be considered.  
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Other advanced treatment options in advanced PD with motor fluctuations and hyper- 
and dyskinesias include duodopa and apomorphine. Duodopa is a liquid preparation of 
levodopa and a decarboxylase inhibitor, and can be administrated by an intra-
intestinal pump. The pump itself is then carried externally, but the catheter tip is 
placed in the duodenum or proximal jejunum. The pump is normally set to deliver a 
morning bolus and a daytime maintenance dose, supplemented by bolus doses as 
needed. Apomorphine is a non-selective dopamine agonist used in PD patients with 
on/off symptoms when other drug regimens no longer can alleviate the situation. 
Apomorphine is like duodopa delivered by an external pump, but as a continuous 
subcutaneous infusion. Apomorphine can induce severe nausea and antiemetic 
medication must be given to patients when using the drug.   
 
Parkinson surgery 
The history of surgical treatment of PD is much longer than the history of modern 
medical treatment for PD. Speelman and Bosch suggested in their 1998 review of the 
history of Parkinson surgery [75] to divide the history of Parkinson surgery in two 
main époques; the first being the époque of open surgery from 1912-1947 and the 
latter being the époque of stereotactic surgery from 1947 [75] – although the 
delineation between these two époques is not completely clear cut, neither in 
methodology nor chronology . However, it could at present, 17 years after Speelman 
and Bosch published  their comprehensive review of the history of PD surgery, 
perhaps be more correct to divide the history in three important époques: Open 
lesioning (1912-1947),  stereotactic lesioning (1947-1991) – and from 1991 onwards, 
the new époque of Deep Brain Stimulation (DBS).  
 
Open lesioning   
René Leriche from 1912 started to perform bilateral cervical rhizotomy in order to 
relieve PD symptoms [76]. This is likely to have been the first systematic attempt to 
treat PD symptoms surgically [75].  Rhizotomy had just been introduced in 1911 as a 
possible way to ease spasticity [77]. Leriche reported some reduction in tremor and 
improvement in functions of the upper extremity [76]. Unfortunately, Leriche’s results 
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could not be reproduced by other surgeons. Later attempts on open functional surgery 
aimed the lesioning at different levels of the pyramidal tracts. Corticotomy to treat 
tremor was introduced by Bucy in 1937 [38], and he later moved on to perform 
lesioning in the corticospinal tract for PD symptoms. In 1939 Russel Meyers started to 
perform transventricular surgery on the basal ganglia to reduce PD motor symptoms 
[75]. The first patient had the head of the caudate nucleus removed, with good effect. 
Contemporary neurologists was of the opinion that the basal ganglia for all surgical 
purposes was a zone of “noli me tangere” – a no touch zone – as it was believed to be 
closely involved in consciousness.  The approach was abandoned around 1947 due to 
the high mortality of the procedure, but it also contributed to the emerging perception 
of the importance of the basal ganglia in the ethiology of PD and their efferent 
connections as targets for PD surgery.  
 
Stereotaxy - the development of the technique  
The basic principles of stereotactic surgery are actually fairly simple. The brain is 
introduced into a fixed, Cartesian (three-orthogonal axis) coordinate system, where all 
minuscule points in the brain has its own set of unique coordinates. This allows for 
precise navigation during surgery – if combined with a precise atlas over the location 
of various brain structures and landmarks from the individual patient or if the 
coordinate system is fused with the patient’s own CT and/or MRI scans. However, the 
accuracy of stereotactic procedures have always relied on a multitude of sequential 
steps from preoperative planning to the surgery itself , where any inaccuracy – 
however minor - in any of the steps can accumulate into a potentially crucial final 
inaccuracy if left unchecked.  
The history of stereotactic surgery has earlier been claimed to have originated with 
Carl Dittmar (1844-1920) who used a guided system to perform incisions in the 
medulla oblongata in rabbits at the Institute of Physiology, Leipzig, Germany, 
described in his 1873 paper [78]. This notion has been challenged by the argument that 
what Dittmar really invented was a supportive arm to help incisions rather than a 
device to help guide the surgeon to the anatomical structures [79]. Dittmar’s device 
was never used in humans.  
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The Russian anatomist Zernov in Moscow on March 22nd 1889 demonstrated an 
“enchephalometer” [80]. The device was used clinically in humans on several 
occasions [79, 81]. So was the sequel invention, an instrument called the “brain-
topograph” also introduced in Russia, by the neurologist Rossolimo [79]. These early 
devices were both designed to locate targets for surgery in the human brain. The 
“brain-topograph” attached to the head with four screws, and bolstered a perforated 
“helmet” where into a probe could be inserted under guidance. But neither of these 
devices employed a coordinate system, and thus cannot be regarded as true stereotactic 
devices.  
Consensus is that the first device to be truly stereotactic is the landmark Horsley-
Clarke frame from 1908 by Horsley and Clarke [82, 83].  
 
Original Horsley-Clarke instrument 
Horsley and Clarke both worked at the University College London Hospital, Sir Victor 
Horsley as a neurosurgeon and Robert Henry Clarke as a surgeon, anatomist and 
physiologist. Horsley and Clarke coined the term stereotaxic (their original spelling), 
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based on their apparatus’ ability to lead a moving instrument precisely in a 3D, 
orthogonal frame of reference. The first version of the frame was constructed for 
Clarke in 1905 under the name “Clarke’s stereoscopic instrument employed for 
excitation and electrolysis”. Horsley and Clarke used this first instrument to do 
lesioning in the cerebellum in monkeys with electrolytic injections in 1906 [81, 83] 
before introducing the Horsley-Clarke frame in 1908 in their classical publication in 
Brain [82]. In this paper they offered a description of the stereotactic instrument itself, 
an anatomical atlas, and methods on how to perform stereotactic procedures – in their 
own words: "by this means every cubic millimetre of the brain could be studied and 
recorded." [82]. The localization of targets relied on the relationships between 
landmarks on the skull (external auditory canals, inferior orbital rims and midline) and 
various anatomical structures within the brain. Cranial fixation points established the 
baselines of a three-dimensional Cartesian stereotactic coordinate system, in which the 
skull and brain of the experimental animal would then be fixed. The high variability in 
humans between external skull landmarks and anatomical structures in the brain, 
rendered the Horsley-Clarke frame and method unusable in humans. Clarke wanted to 
bring the new technology to use in humans and in 1912 he delivered a patent 
application for a stereotactic instrument for human use. It is claimed that Clarke’s 
advocacy for moving on to apply stereotaxy in humans alienated him from Horsley 
and was one of the reasons why their cooperation ended [81]. Regardless, Horsley and 
Clark contributed significantly to paving the way for stereotactic surgery in humans 
four decades later, and their frame was used in animal experiments for many years. 
The original instrument is reported to have been used for the last time in London in the 
1950’ies [83]. 
In 1918 Aubrey Mussen at the Montreal Neurological Institute, Canada designed an 
improved version of the Horsley-Clarke frame and had it built in London [84]. The 
concept was based on attaching the frame to the external auditory canals and the 
infraorbital ridge, and a new stereotactic anatomical atlas Mussen had made. However, 
Mussen could not find surgeons who would like to try the equipment clinically and it 
was never tried on humans. 
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For the next decade and a half the development of stereotactic approaches to the 
human brain nearly came to a halt. But in 1932 a copy of the original Horsley-Clarke 
device was built at the Northwestern University Medical School and was subsequently 
used there by Ranson and Ingram for investigation of nucleus ruber and hypothalamus 
[85]. The variance between individuals in correspondence between surface landmarks 
and brain structures remained a challenge, especially in the deeper laying anatomical 
targets. But in the 1920’ies Walter Dandy had in the meantime invented 
ventriculography which allowed for the visualization of intracranial anatomic 
reference points and landmarks. The pineal gland and the foramen of Monro was first 
used, and upon the subsequent advent of positive contrast for intraventricular use 
the anterior and posterior commissures were also used as intracranial landmarks. 
Spiegel and Wycis exploited these new intracranial landmarks when they in 1947 
published their first work on stereotactic surgery in humans [86]. 
 
Spiegel and Wycis 1959 
They used a modified Horsley-Clarke apparatus as setup, and used 
pneumoencephalograms pre- or intraoperative to localise the pineal gland and the 
foramen of Monroe. Their objective was to make lesions in the dorsal median nucleus 
of the thalamus as a less invasive and destructive alternative to the then-popular frontal 
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lobotomies. However, in their original publication Spiegel and Wycis also suggested 
other application for stereotactic lesioning in humans, to alleviate pain, drain cystic 
lesions – and to treat movement disorders [86]. After they made the first stereotactic 
atlas of the human brain in 1952, the way lay open for trying out new targets and 
indications. The atlas consisted of a series of photographed coronal brain slices cut at 
specified intervals in relationship to intracranial landmarks, and with a millimetre 
reference grid around the borders of each coronal section. 
In 1947, the Swedish neurosurgeon Lars Leksell visited Wycis in Philadelphia. Upon 
his return to Sweden, he in 1949 presented his own stereotactic apparatus which 
instead of a Cartesian coordinate system employed three polar coordinates (angle, 
depth and anterior–posterior location). This so-called ‘‘arc-quadrant’’ device provided 
more flexibility in choosing probe entry point and trajectory. The Leksell frame 
quickly became the apparatus of choice as the medical society ventured into the era of 
stereotactic surgery for PD. 
Stereotactic lesioning in PD 
Initial attempts with deep brain lesioning for tremor and rigidity in PD focused on 
Globus Pallidus internus (GPi) and the ansa lenticularis as targets. Results differed 
between centres, but Svennilson et al, from Leksell’s group at Karolinska, reported 
good effect on tremor, rigidity and functions of daily life in a series of 81 patients 
treated with pallidotomy [87]. Due to the poor response on tremor in many patients 
after pallidotomy, new targets were sought. Hassler and Riechert in 1954 introduced 
new targets in the thalamus which seemed to offer more tremor control in PD and 
lower risk of complications than the richly vascularized areas of Globus Pallidus and 
capsula interna [88]. Gradually, into the 1960’ies, most centres turned to perform 
thalatomies for symptom relief in PD rather than pallidotomy. By 1969 more than 
37.000 stereotactic operations had been performed and recorded, most for PD [89]. 
Overall morbidity was less than 10% and mortality less than 1%. Targets were in the 
thalamus (VOP, VIM) or in the subthalamic area. Selection criteria had been 
established, and made 12-15% of PD patients eligible for surgery with expected effect 
on tremor and rigidity in 80-90 % of operated patients [89]. 
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Despite these convincing results, stereotactic lesioning all but came to a total stop 
shortly after Cotzias introduced L-dopa [45], with most centres ceasing to perform 
stereotactic lesioning in PD [75]. 
Resurgence of stereotactic surgery in the treatment of PD 
By the mid-70’ties it was clear that L-dopa therapy could not halt disease progression 
in PD, and that symptom relief in the long term often required high doses often 
causing severe side effects. New interest was spurred in thalatomies as a supplement to 
L-dopa therapy in selected patients, and it was demonstrated that L-dopa therapy did 
not decrease the known beneficial effects of thalatomy, nor vice versa [90]. In the 
70’ties CT scanners were increasingly common in centres worldwide. In 1978 Russel 
Brown presented a new method of stereotactic localisation of targets, by direct 
imaging on CT scans of intracranial structures with fiducial markers defining their 
spatial position [91]. Subsequently, stereotactic localization through neuroimaging 
rapidly became the standard. It was incorporated in several stereotactic frame systems, 
notably the Leksell system [92], in the Brown-Roberts-Wells (BRW) [93] and in the 
Cosman-Roberts-Wells (CRW) system [94]. Globus Pallidus was also revived as a 
target, with favourable outcomes reported on tremor, rigidity, hypokinesia and also on 
levodopa induced hyperkinesia [95]. In this period electrical test stimulation was 
introduced as a way to locate and distinguish specific sites within the brain 
peroperatively.  
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Diagram of the CRW frame setup. 
Deep brain stimulation 
Deep brain stimulation (DBS) is a technology and a method in which one or two 
implanted, intracranial electrodes are used to deliver continuous high frequency 
electrical stimulation to targets in the brain. The basic function of the device resembles 
that of a heart pacemaker, and the notion “brain pacemaker” has been used in patient 
education in order to better communicate how the DBS technology really works. DBS 
has been used to treat movement disorders (PD, essential tremor and dystonia), 
psychiatric symptoms, chronic pain, obsessive compulsive disorders including 
Tourette’s syndrome - and epilepsy. Different symptoms are treated with DBS in 
different targets in the brain.  
The high frequency electrical stimulation (>100Hz) has been thought to create a 
functional, reversible lesion, where the effected neurons are paralyzed and cease to 
generate axonal outflow. This explanation is likely to be too simple. Many 
mechanisms for the effect of DBS in the subthalamic nuclei (STN-DBS) have been 
suggested. Ortodromic axonal stimulation of the cortex has been suspected to be 
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involved. However, the effect by which DBS works in the brain is not yet fully 
understood. 
The development of DBS  
In 1987 the Grenoble-based research group of the neurosurgeon Alim-Louis Benabid 
and the neurologist Pierre Pollak published their work on continuous high frequency 
stimulation in the thalamus to treat tremor [96]. The effect of the chronic thalamic 
stimulation was convincing, but the beneficial effect of the stimulation in the thalamic 
target was limited to tremor suppression and had no effect on other PD symptoms. In 
1990 animal studies in MPTP treated monkeys indicated that dopaminergic 
deafferentation caused hyperactivity in the STN [97] and that supressing STN outflow 
by selective lesions could reverse rigidity and akinesia [98, 99]. 
  
Alim-Louis Benabid 
The Grenoble group built on these results, and in 1994 they published the results of 
chronic high frequency stimulation in the subthalamic nuclei in two PD patients [100]. 
The publication led to a rapid spread of the method of STN-DBS and several smaller 
studies showed promising effect on motor symptoms in PD. By the end of the 
millennium STN-DBS was established as a proven treatment option in advanced PD. 
In March 2001 the first STN-DBS for PD in Norway was performed at Rikshospitalet 
[9]. 
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General description of the operative STN-DBS procedure  
Preoperative CT and MRI scans are necessary for planning the stereotactic electrode 
trajectories. MRI is variably conducted before or after the mounting of the stereotactic 
frame on the patient’s head, but the CT scan is always done with the frame mounted to 
orientate the external markers with the cranial and intracranial structures. The 
stereotactic frame is mounted under local anaesthesia, and in the CRW system the 
frame is fixed to the patient’s skull by 4 screws. 
 
Mounting of the CRW frame, application of local anaesthesia. 
 
If a preoperative MRI scan taken before the mounting of the frame is blurred by 
movement artefacts, e.g. by tremor, a new MRI is preformed after the patients head is 
securely fixated in the CRW frame. This is strenuous for the patient, but sometimes 
necessary in order to secure the required image quality. 
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CT scan after mounting of the CRW frame 
Planning of trajectory and targets is then done on a computerized planning system, 
after fusion of the CT and MRI scans. The aim is to place the targets accurately in the 
dorsolateral sensory-motor part of the STN nuclei, and to plan safe trajectories 
avoiding the vascularized sulci, visible blood vessels and ependymal ventricular walls. 
In the STN all neurons with sensorimotor responses are found in the dorsolateral part, 
and this part of the STN has been the preferred target for STN-DBS [101]. In this part 
of the STN the neurons seem to be somatotopically arranged. Neurons associated with 
arm movements are located most lateral, neighbouring more medially placed neurons 
associated with oromandibular function which are again flanked on the medial side by 
neurons involved in leg movements  [102]. The medial tip of the STN represents its 
limbic part and is connected to the limbic part of the substantia nigra and the ventral 
tegmental area [103]. Neurons connected to associative circuits are located 
ventromedially in the STN [104]. Known complications to chronic STN stimulation 
include psychiatric side effects [105, 106] and linguistic side effects. Linguistic side 
effects have been induced in patients by applying test stimulation in the associative 
part of the STN [107]. Thus, the functional anatomy of the STN may be important in 
explaining direct, reversible side effects in STN-DBS, and underscores the need for 
precise targeting during the surgical procedure. 
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Planning of targets and trajectories in the BrainLAB planning suite, 1 
 
Planning of targets and trajectories in the BrainLAB planning suite, 2 
After planning the targets and the trajectories the patient is placed on the operating 
table in a beach chair position, in order to reduce peroperative CSF loss and brain shift 
and to make intraoperative neurological examinations possible.  
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Patient positioned in order to minimize CSF loss 
Equipment for fluoroscopy is positioned for recording the electrode positions 
preoperatively, and the surgical field dressed in sterile draping. 
 
Operative setup 
The burr holes in the cranium will normally be placed approximately 2 cm lateral to 
the midline and 2 cm anterior to the coronal suture. The dura and the arachnoid are 
incised central in the burr hole, and the underlying gyrus is visualized. Pia is cauterised 
29 
 
in a point to allow entry of the cannula later used for electrode insertion. The first 
electrode inserted will be the test electrode, with a 20 μm tip allowing 
electrophysiological recordings from a single neuron.  
 
Electrophysiological recordings intraoperatively. 
If typical STN recordings are obtained near the planned target, this area is chosen for 
test stimulation. If not, a new trajectory parallel to the first, but 2 mm apart is tested. 
Up to five different trajectories can be tested in this setup. When the decision is made 
on the preferred trajectory, the test electrode for micro electric recordings is removed 
and replaced by a macro electrode meant for permanent implantation. The permanent 
intracranial electrodes will normally have multiple poles at the tip with spacing 
between. In our setup, a permanent lead (Medtronic 3389) with 4 electrodes at the tip 
and 0.5 mm spacing was used. Test stimulation is then performed from the permanent 
electrode in different levels in the area of clear STN signal recordings. 
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Insertion of the permanent electrode through burr hole under stereotactic guidance from the CRW frame. 
Test stimulation is always conducted in concert with clinical testing for effect on 
motor symptoms and to reveal side effects. If clinical testing confirms the correct and 
acceptable placement of the permanent electrode, the lead is fixed in this position by 
permanent implementation of a fixation device attached to the burr hole. The lead 
position will be recorded with fluoroscopy, as a precaution against later intraoperative 
shift in the position of the electrode tip. The procedure is repeated on the contralateral 
side. 
 
 Clinical testing under test stimulation. 
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After bilateral implantation of permanent electrodes, the lead ends are left 
subcutaneously posterior to the patient’s ear on the side decided for pulse generator 
implantation. The patient is released from the stereotactic frame, before being placed 
under general anaesthesia.  
 
Patient just released from the CRW frame, permanent leads implanted bilaterally. 
Under general anaesthesia, a pulse generator (Kinetra, Medtronic) is implanted 
subcutaneously in the pectoral region, preferably on the off-hand side.  
 
Planning the position of the pulse generator. 
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Connecting leads are tunnelled under the skin up to the junction point posterior to the 
patient’s ear.  
 
Connecting the intracranial and extracranial leads. 
At the end of battery life, non-rechargeable pulse generators must be changed. This 
requires a small operation in local anaesthesia. Today, rechargeable pulse generators, 
which can be charged transcutaneously, are becoming more and more common.  
All poles on the electrode, and the pulse generator itself, can be set to be positive or 
negative poles. The voltage, frequency and pulse width of the stimulation current can 
all be adjusted. Thus, the size and shape of the area of stimulation can be modulated. 
The objectives are to achieve maximum symptom control with minimum side effects. 
Over the first months after implantation of a DBS system in PD patients, the voltage of 
stimulation is gradually increased as dopaminergic medication is gradually reduced. 
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Aim of the thesis 
The overall aim of this thesis has been to investigate the long term clinical 
development in Parkinson’s disease (PD) patients after surgical treatment with 
continuous high frequency electric stimulation in the subthalamic nuclei (STN-DBS). 
Important goals have been to study the long-term clinical effects on the various 
clinical symptoms in PD, including effect of STN-DBS on disease progression and 
survival as well as the efficacy and safety of the treatment.  
We decided to conduct our scientific evaluation of the long term clinical disease 
progression in patients with PD after STN-DBS by asking four major questions: 
1. Could we confirm the stable effect on dopaminergic motor symptoms, the 
safety of the procedure and reduction of medication reported in a number of 
small international studies in our large material recruited in the homogenous 
setting we benefit from in Norway? 
2. Could STN-DBS be demonstrated to have any disease modulating or 
neuroprotective effects in PD, i.e. by halting or slowing down symptom 
development or reducing mortality? 
3. What long term positive or detrimental effects does STN-DBS have on axial 
motor symptoms in PD? 
4. What long term positive or detrimental effects does STN-DBS have on non-
motor symptoms in PD? 
 
Through the 4 papers in this PhD we attempt to elucidate these questions 
systematically. 
Materials and methods 
The recruitment base for the study populations included in the thesis have been 
patients with advanced PD treated with STN-DBS. All 144 PD patients treated with 
STN-DBS at Rikshospitalet from 2001 and until the end of 2007 have been 
prospectively followed with standardized examinations until the end of 2008. 2001 
was when this treatment option first was made available to PD patients in Norway. 
Likewise, all 28 PD patients operated with STN-DBS at the Stavanger University 
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Hospital from this treatment was first offered at the hospital in 2003 and until 2006 
when the hospital no longer preformed STN-DBS, were also followed prospectively 
until 2012. The examination program at Stavanger University Hospital was similar to 
the examination program at Rikshospitalet.  
To be eligible for surgery patients had to have a clinical diagnosis of PD, age under 75 
years, levodopa-responsive motor symptoms with severe motor complications, and/or 
resting tremor with unsatisfactory levodopa response.  Patients were not considered 
eligible for surgery if they had dementia, had had major psychiatric illness, had 
marked atrophy on cerebral MRI or had other general contraindications to surgery. 
The preoperative examination included an interview, neurological examination, and a 
levodopa test comparing the UPDRS motor score in the off-medication and best on-
medication state. Postoperative evaluations were carried out approximately 3 months 
after surgery, 12 months after surgery and then annually.  
The Regional Committee for Medical and Health Research Ethics in Western Norway 
approved the studies.  
In study 1 all 144 PD patients operated at Rikshospitalet was followed in order to 
show the clinical outcome and mortality in the long-term after STN-DBS. The patients 
were examined preoperatively and thereafter at 12 months intervals up to 60 months 
postoperatively. 131 patients had data preoperatively and at least 1 assessment 12 
months after surgery and could be included in the analyses for treatment effect. 
Descriptive statistics were calculated for baseline demographic and clinical data. Non-
parametric tests were used for group comparisons. Possible associations of various 
demographic and disease/treatment-related factors on treatment efficacy was explored 
using Mann-Whitney U tests and Spearman Rank correlation coefficients, and then 
studied with regression analyses. To demonstrate mortality over time, Kaplan-Meier 
survival curves were constructed. 
In order to demonstrate differences in the long term clinical development of PD in 
study 2-4, a reference population of comparable, non-operated PD patients was 
required. For this purpose a population-based prevalence study conducted with patient 
recruitment between September 1992 and May 1993 was taken into use [48]. The 
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prevalence study took place in Rogaland County, Western Norway and used all 
available sources to identify and include all PD patients in the general population of 
the county. Hospital files were searched, and general practitioners, nursing homes, 
district nurses, health workers and the Rogaland Parkinson’s Disease society were 
contacted and cooperated.  245 patients with PD were identified and 239 patients could 
be included in the subsequent study population. The study population was followed 
prospectively with standardized examinations in 1997 (144 patients attended) and 
2001 (89 patients attended). This sectional population of PD patients was thus 
followed in the years 1992 through 2001. As such, the patients were followed 
prospectively in the very last decade before STN-DBS was made available in Norway. 
By using the same exclusion criteria for surgery on this population as for the operated 
patients, a reference population of PD patients could be established. The patients in the 
reference population that were prospectively followed for 8 years were eligible for 
STN-DBS, but at the time STN-DBS was not a treatment option. 
In study 2, the operated patients from Rikshospitalet were compared to the non-
operated patients from the reference population with regard to disease progression and 
survival. Disease progression was measured by changes in motor score on the Unified 
Parkinson’s Disease Rating Scale (UPDRS). Individually age matched groups of 
patients were established to further increase the likelihood to discover any differences 
in disease progression or mortality between STN-DBS operated and non-operated. 
Age was chosen as the variable for matching as previous studies have shown that age 
is the most important independent risk factor for rapid increase in UPDRS motor 
score. Differences in development of UPDRS motor scores were analysed using 
analysis of covariance (ANCOVA) with follow-up time, age and sex as covariates. We 
examined for differences in mortality using Cox regression to assess different hazard 
ratios (HRs) for death after baseline. 
In study 3 we studied the development of non-dopaminergic motor symptoms in PD 
patients operated with STN-DBS at Stavanger University Hospital in the period the 
hospital preformed such surgery, 2003 through 2006. In total 28 patients were 
operated, and 16 was still alive in 2012 and had sufficient clinical data to be included. 
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The development of parkinsonism, postural instability and gait difficulties (PIGD), 
freezing of gait (FOG) and falling was recorded prospectively in these patients 
preoperatively and at postoperative outpatient controls. Again, the development in the 
operated patients was compared to the development of the same symptoms in PD 
patients from the reference population deemed eligible for surgery. For improved 
reliability of findings, the operated patients were individually matched to comparable 
non-operated control patients from the reference population, based on their first 
postoperative control scores by means of propensity scores matching. The propensity 
scores matching took into account gender, age > 67, levodopa equivalent daily dose 
(LEDD), total UPDRS motor and ADL (activity of daily living) score and mean 
UPDRS tremor and PIGD scores, PIGD type,  
Selection, surgical procedure, implants and programming in Stavanger and Oslo 
The procedures pertaining to STN-DBS treatment in the PD centres of Oslo and 
Stavanger have been quite similar, both pre-, intra- and post operatively. The 
procedures for patient selection, the surgical procedure and the post-operative 
programming algorithm used in Oslo [5] was in general adapted in Stavanger. The 
criteria for selecting patients for STN DBS were that the patients had a diagnosis of 
PD, were under 75 years of age, had levodopa-responsive motor symptoms with severe 
motor complications and/or resting tremor with unsatisfactory levodopa response; and 
did not have dementia or major psychiatric illness, marked cerebral atrophy on MRI, 
or other contraindications to surgery.  The surgical procedure and procedures for 
localizing the STN by MRI, intraoperative microelectrode recording and micro- and 
macrostimulation testing were based on procedures from the major centres in Europe 
[108].  
All patients stopped their dopaminergic medication 24 hours before surgery. No 
benzodiazepines or similar drugs were administrated in the morning before surgery. 
After preoperative MR imaging, the patients’ head was shaved.  A CRW™ stereotactic 
frame (Radionics, MA, USA) was mounted under local anaesthesia and stereotactic 
3D CT imaging was performed with the frame on the patients head. The images were 
fusioned on the iPlan™ computer-aided neuronavigation system (BrainLAB, Munich, 
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Germany). The margins of the STN were visualized, the image guided target was 
placed in the dorsolateral STN bilaterally and the surgical trajectories were planned 
accordingly, avoiding the ventricles and blood vessels. Burr holes were placed 
approximately 2 cm anterior to the coronary suture and 2 cm lateral to the midline, 
under curved incisions in the scalp. The Dura mater was incised, and the underlying 
Pia mater was punctuated with diathermy over the gyrus in the centre of the burr hole. 
The phantom in the CRW frame system was used for verification of the surgical setup 
before inserting the cannula for the electrodes. The localization of the site of the 
permanent electrode implant (Lead 3389, Medtronic, MN, USA) was refined by a 
combination of intraoperative microelectrode recordings (LeadPoint™, Medtronic, 
MN, USA) and intraoperative stimulation. The microelectrodes were introduced one-
by-one and recordings were performed from 10 mm above the anatomical target and 
with 0.5-1 mm steps. Typically, high-frequency, spontaneous, movement related 
activity and tremor-related cells were identified within the STN. Acute STN-
macrostimulation improved contralateral rigidity and akinesia, and suppressed tremor 
when present. Further microelectrodes were only introduced following insufficient or 
atypical findings in the first trajectory. The electrodes were fixed to the skull and 
connected to a Kinetra™ (Medtronic, MN, USA) neurostimulator fully implanted 
under general anaesthesia. During the weeks after implantation, stimulation parameters 
were adjusted following usual algorithms for programming [109], gradually increasing 
stimulation until good effect and no side effects and simultaneously reducing 
dopaminergic medication.  
Results 
x Study 1 describe the clinical improvement and subsequent progression in the 
cardinal, motor symptoms in PD in a very large material consisting of all 144 
PD patients operated with STN-DBS at Rikshospitalet in the years 2001 
through 2007. The study set out to confirm the stable efficacy of long-term 
subthalamic stimulation in selected patients with advanced PD.  
x Study 2 investigated the postulated disease modifying or neuroprotective effect 
of STN-DBS by comparing the rate of deterioration of parkinsonism and 
mortality over time in two selected and matched groups of patients with PD 
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with and without surgery. The study investigated both clinical disease 
progression and mortality in the two study groups. 
x Study 3 examined short- and long-term impacts of STN-DBS on the 
development of the PIGD (postural instability and gait difficulties) phenotype, 
FOG (freezing of gait) and falls, comparing the development in matched groups 
on operated and non-operated patients with PD. 
x Study 4 explored how non-motor problems develop in patients with and without 
STN-DBS.  The study set out to elucidate how non-motor problems of 
advanced PD develop with and without treatment with STN-DBS, on the 
presumption that such knowledge could help making the right decisions on 
when to perform this therapy for eligible patients. 
 
Study 1 
The results in study 1 confirm earlier findings that STN-DBS is an efficient, stabile 
and safe treatment option for motor symptoms in selected patients with advanced PD 
[1, 110]. Average improvement on UPDRS motor scores as measured a year 
postoperatively was 53 % (95% CI 48-57 %)3. In 2001-2002 the patients had a mean 
UPDRS motor score of 45.2 in off-state, as compared to an average score of 35.3 in 
2006-2007. This did not affect the effect of the surgery in the patients, the average 
annual increase in UPDRS III score being 3.2 points1. This matches well the annual 
UPDRS III increase in a contemporary population study (3.3 point average annual 
increase in UPDRS III) [111].  Peroperative mortality was 0 defined as no mortality 
during the admission for surgery and within 30 days after surgery. Within the study 
period two deaths probably related to the surgery occurred among the 144 operated 
patients (1.4%). We found a total surgical complication rate of 10 %. A reduction in 
the STN-DBS patients’ preoperative off-state UPDRS III scores was observed in the 
period from 2001 to 2007. The reduction was statistically significant (Kruskal-Wallis, 
P = 0.02). 
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1Figure 1 from study 1: The development in UPDRS motor score in off during follow-up, patients divided after 
year of surgery. 
Mean LEDD was reduced by 49%.  The effect on motor symptoms was shown to be 
stable over time, and the effect was not associated with gender, age, previous PD 
surgery, preoperative LEDD, nor the neurosurgeon preforming the procedure. A 
gradual change in the symptom severity over time in the operated patients was 
observed, with STN-DBS treated patients in average having more severe symptoms 
during the first years after the treatment became available in Norway.  
It was observed that two patients from the 144 committed suicide. That gives a suicide 
frequency of 1.4%, as compared to international reports of a suicide frequency of 
0.45% [112]. Overall survival is shown in figure 2 under2. There was a trend towards 
more severe symptoms as measured by UPDRS III in the patients who died during 
follow-up, as well as a tendency towards higher age at baseline in the patients who 
died during follow-up3,4. 
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2Figure 2, study 1: Kaplan-Meier curve of patient survival during follow-up.2 
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3Figure 3, study 1: Distribution of UPDRS III score at baseline for patients alive and deceased at the end of 
follow-up. 
 
 
4Figure 4, study 1: Distribution of age at the time of surgery for patients alive and deceased at the end of 
follow-up. 
 
 5Table 1 from study 1. 
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The results from study 2-4 span various aspects of short and long term clinical 
symptom development after STN-DBS.  
Study 2 
In study 2 we found no significant difference between the STN-DSB operated patients 
and the non-operated patients in the reference group in progression of UPDRS motor 
scores over time, nor any differences in long-term survival. After age-matching, the 
results were the same with no significant differences in disease progression between 
operated and non-operated patients6. There were more females in the reference 
population than in the operated group, but an analysis of variance (ANOVA) could not 
demonstrate any interaction between gender and annual UPDRS change. Age at 
baseline was the strongest predictor for mortality, and there was a trend towards higher 
mortality in the surgery group7.   
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6Table 1 from study 2 
 
UPDRS-III scores were measured in the medication and stimulation ‘on’ state. Baseline data for further disease 
development in the operated group was scored 3 months after initiation of STN-DBS.  
 
7Cox regression on matched patients 
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Study 3 
In study 3 we again demonstrated marked and rapid reduction in UPDRS III scores in 
patients after STN-DBS, with a reduction in the operated patients’ mean UPDRS III 
score from 27 to 18. Tremor, bradykinesia, rigidity and PIGD showed major 
improvement after STN-DBS. The two patients in the operated group with 
preoperative FOG did not experience this at the first follow-up after surgery. The 
findings are summarized in the table 1 rendered below8.  
8Table 1 in Study 3.  
 
In the long term, we found that PIGD symptoms dominated in all operated patients at 
the final visit. FOG and falls also increased during postoperative follow-up, and at last 
visit approximately 50% of the patients had these symptoms. The development of 
PIGD score and the proportion with PIGD dominance as well as FOG and falls 
developed similarly in the historical controls, also after individual matching9,10. For 
tremor and rigidity, there was a minor annual reduction in UPDRS scores for the 
operated patients whilst the non-operated group showed marked increases during 
follow-up10. Bradykinesia increased in both groups at a similar rate10. 
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9Table 2 in study 3.  
 
 
10Table 3 in study 3  
 
 
Study 4 
In study 4, dementia was found to develop over time in both operated and non-
operated patients. As dementia is an exclusion criterion for surgery, no patients in the 
study groups had clinical dementia at baseline. At the final visit 31 % of the patients in 
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the operated group had developed dementia, and 46 % in the reference group. The 
average MMSE scores changed from 28.4 3-6 months after surgery to 23.4 at final 
visit in the STN-DBS group and from 28.3 to 22.6 in the reference population. After 
individual matching, the results were similar. Sleep disorders as measured by ESS and 
EDS, as well as insomnia, developed similarly in the operated and non-operated 
populations. Comparable findings were present for apathy. Depressive symptoms as 
measured by MADRS score were stable and comparable between the two groups 
during follow-up. Interestingly, fatigue as measured by FSS score and the proportion 
of patients with a FSS score ≥ 4 increased significantly in the STN-DBS group from 
baseline to last visit. At the final visit 87 % of the patients in the STN-DBS group 
(n=16) had FSS ≥ 4. In the matched groups, the percentage of operated patients (n=12) 
with FSS of 4 or above also increased. 45% of the STN-DBS patients had an FSS ≥ 4 
at baseline, increasing to 75% after one year and at 91% at the final visit. Of the non-
operated patients only 55 % had an FSS ≥ 4 at final visit before matching, rising 
slightly to 67 % after matching. Thus, the comparison of the matched groups also 
demonstrated a difference in the frequency of fatigue at the final visit. Preoperatively, 
25 % of the STN-DBS patients reported hallucinations, but these were gone at the first 
postoperative visit 3-6 months after surgery as no patients reported hallucinations. 
During follow-up, hallucinations increased again in the surgery group, and at last visit 
half of the patients reported hallucinations. In the reference group, 37 % reported 
having hallucinations. However, after individual matching the difference between 
operated and non-operated patients disappeared, with 50 % of the patients reporting 
hallucinations at last visit in both groups.   
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11Table 1 in study 4.  
 
12Table 2 in study 4.  
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13Table 3 in study 4.  
 
 
Discussion 
Methodological considerations 
The ideal way of studying the long-term clinical effects of STN-DBS would probably 
be a double blind randomized control trial. Sham surgery has been advocated to 
document the effect of surgical therapies for PD [113, 114], and has played a role in 
studying the effect of cell implants to treat advanced PD.  However, sham surgery 
remains highly controversial as a research tool even for novel, experimental treatments 
[115], and is difficult to perform blinded especially to the investigators. STN-DBS can 
no longer be regarded as an experimental or exploratory treatment, as it has been an 
established treatment option for more than a decade and a half.  Thus, randomizing 
patients with advanced PD eligible for STN-DBS treatment to therapy or sham surgery 
would certainly be deemed unethical in Norway and probably most other countries, 
under the obligation to offer all patients in a therapy trial the best possible established 
treatment. To document the effect of GPi-DBS (bilateral deep brain stimulation in the 
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Globus Pallidus internus) treatment for dystonia, short studies [116-118] have been 
conducted bypassing these ethical considerations to some degree. Patients deemed 
eligible for GPi-DBS were included and operated. The patients were then randomized 
to having the pulse generator switched on, thus receiving active therapy, or to have the 
pulse generator in stand-by thus receiving no stimulation. The patients were followed 
for three months comparing the clinical development in dystonia symptoms. A similar 
approach could be taken to study the effects of STN-DBS in the short term. However, 
keeping the stimulation off in an implanted system over several years in order to study 
long-term differences in the development of clinical symptoms caused by STN-DBS 
would clearly not be ethical given the risk of complications to the surgery to all 
patients and the potential beneficial effects lost to the patients randomized to 
stimulation off. 
We decided to find the best available substitute for a randomized control trial in order 
to demonstrate the effects of STN-DBS as an intervention in selected patients. 
Fortunately, our colleagues at The Norwegian Centre for Movement Disorders had 
conducted a population-based study in the early nineties [48]. Our colleagues included 
all PD patients from a Norwegian county at a given time, and followed them 
prospectively over the following decade with standardised examinations as part of a 
longitudinal study of disease progression, very similar to the setup later at 
Rikshospitalet and Stavanger University Hospital for the STN-DBS patients. This 
created the opportunity to compare the progression of clinical symptoms in two similar 
populations, in which none of the patients followed in the nineties had the option of 
STN-DBS, whilst the STN-DBS patients from the following decade were recruited 
nationwide with all Norwegian patients with PD filling the criteria for surgery in 
principle had the option of STN-DBS treatment (although some patients were not 
operated due to limited capacity).  
Arguably, this approach brings the studies in paper 2-4 as close to the ideal 
randomized trial as ethically possible given the ethical and practical considerations 
above - by being the closest possible setup to a two armed cohort study comparing 
surgery and best medical treatment to best medical treatment alone. However, this still 
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gives rise to a number of methodological considerations and shortcomings which 
could bias our findings.  
It is not possible to rule out placebo effects from the surgical intervention in our set-
up, although such effects would be expected to occur most frequently in the short-term 
after surgery. The long follow-up time in this thesis might reduce the impact of 
placebo effects when regarding long-term results.   
When establishing the reference population from the population study in 1992 and 
1993, we excluded patients after the same exclusion criteria as for PD patients 
considered for selection to STN-DBS treatment the following decade. This allowed us 
to establish a population of PD patients eligible for STN-DBS treatment, from a 
decade when Norwegian PD patients had no access to such treatment. However, 
excluding non-operable or non-eligible patients from the reference population does not 
equal that all patients in the resulting reference population would have been operated if 
STN-DBS was available as a treatment option at the time. There were some 
differences between the two populations. Individual matching of patients from the 
operated and non-operated populations were carried out to mitigate this, and to 
increase the possibility of uncovering significant differences in long term clinical 
development [6-8]. The patients in the reference population were on average 5 years 
older than the operated patients from Rikshospitalet and 6 years older than the 
operated patients from Stavanger University Hospital. There were also gender 
differences between the populations, with the percentage of females varying from 35 
% in the operated patients from Rikshospitalet, 53% in the reference population and 
63% in the operated patients from Stavanger University Hospital. We found higher 
average LEDD at baseline in the reference population recruited in the last decade of 
the past millennium (520 mg) than in the operated patients from the first decade in this 
millennium at Rikshospitalet (448 mg), but lower than in the patients operated within 
the same time frame at Stavanger University Hospital (960 mg). As the non-operated 
study population and the two operated populations hail from two consecutive decades, 
medical treatment options and strategies could have changed over time. This could 
lead to differences in medical therapy approach in the populations. The differences 
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were partially mitigated in the two studies in which the individual matching also took 
LEDD into consideration (study 3 and 4), but still represent potentially confounding 
factors. 
The differences between the two operated populations are also mirrored in the average 
UPDRS-III scores at baseline in best “on”, 27 in the operated patients from Stavanger 
University Hospital and 15 in the operated patients from Rikshospitalet. It was 
demonstrated in study 1 that the patients operated in the first years at Rikshospitalet 
had more advanced PD than the patients operated in the last years of the inclusion 
period [5]. As the two operated populations have not been compared in this thesis, this 
heterogeneity has not directly affected our results here, but the possibility that our 
operated population in study 2-4 may not be fully representative for STN-DBS patients 
treated worldwide cannot be excluded given the differences between patients operated 
in Oslo and Stavanger.  
In studies 2-4, the materials are made up of relatively few patients especially in the 
matched groups of patients. Combined with the lack of a blinded and randomized 
control group, this could have introduced bias in the observed disease development 
both in the short and in the long term. The small sample sizes would reduce the 
chances of demonstrating statistical differences between the groups. Further, because 
only patients with sufficient data could be included there is also a risk of selection 
bias. The need to include only patients with sufficient data in the long term also meant 
that patients who died before the end of the 6-9 year follow-up could not be included, 
thus also introducing a risk of selection bias.  
 
Findings 
Overall, we have demonstrated stable long term effect on the cardinal motor symptoms 
in PD after STN-DBS. The findings of stable, lasting reduction in UPDRS-III scores 
[5, 6] are supported by lasting reduction in average LEDD and in that stimulation 
parameters could be kept largely unchanged during a 60 month follow-up [5]. The 
surgical complication rate was low at 10 % and peroperative mortality were 0[5]. The 
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surgical complication rate was approximately half of what has been reported in 
international literature recently [119]. 
Comparing the progression of PD in operated patients and non-operated eligible PD 
patients, we found no significant differences supporting a disease modulating effect of 
STN-DBS [6]. Also, survival rates showed no significant differences which could 
support a neuroprotective effect of STN-DBS. Indeed, there was a tendency to lower 
survival in the operated group (p 0.091), adding to the conclusion that STN-DBS does 
not seem to halt or slow down the natural progression of PD in patients. Our findings 
match those of other newer long term observational studies [120, 121], increasing the 
reliability of our results despite the weaknesses stated above in “Methodological 
considerations”. However, a recent study by Ngoga et al compared survival in PD 
patients eligible for STN-DBS, in two groups of operated patients and patients opting 
out from surgery after being accepted for STN-DBS [122].  Ngoga et al found 
significantly reduced mortality in STN-DBS operated patients, as compared to the 
non-operated. The differences in death from respiratory causes was the underlying 
significant factor, however, and a neuroprotective effect of STN-DBS was not 
suggested. Our study could contribute to bring the discussion on an alleged 
neuroprotective effect of STN-DBS closer to an end. We believe the research focus 
concerning STN-DBS should now rather be on refining the method and maximizing 
symptom control, by improving the selection of patients, the timing of the procedure 
and the management of side effects.  
Non-dopaminergic motor symptoms become near ubiquitous in PD patients as the 
disease progresses over time and the brain lesions become more widespread. The 
presumably complex pathophysiology behind PIGD, FOG and falls is still not fully 
elucidated, however. It is likely that locomotor areas in the brainstem and midbrain are 
involved in control of balance and gait [19], while dopaminergic structures may play a 
lesser role. Thus, as STN-DBS has been considered a dopaminergic treatment, it 
would accordingly be expected that STN-DBS would have limited effects on PIGD, 
FOG and falls.  However, we found acute improvement in PIGD symptoms 3-6 
months post-surgery, but the acute improvement was followed by long-term 
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deterioration. 6-9 years after surgery all patients in the operated group had PIGD. 84 % 
of the non-operated patients had PIGD at last follow-up (8 years after baseline).  Thus, 
no lasting effect on PIGD symptoms from STN-DBS could be demonstrated.  
Our work supports that non-motor problems in PD develop independently of 
interventions with STN-DBS. This could be expected on basis of the traditional view 
of STN-DBS as a dopaminergic treatment. Still, this knowledge is of importance both 
for the selection of patients for surgery, for timing surgery and when informing PD 
patients of the possibilities and limitations associated with STN-DBS. 
 In our study 4 no patient in any of the groups suffered from mental 
impairment/dementia at baseline. But after 6-8 years of observation 31 % of the 
operated patients and 45 % of the non-operated had dementia after the DSM-III-R 
criteria [123]. When adjusting for the 6 year higher average age in the non-operated 
group, there is seemingly no influence from the STN-DBS procedure on development 
of dementia. Our observed rate of dementia development in operated patients match 
the findings in a recent study following long term development of dementia in 184 
STN-DBS operated PD patients [124]. At baseline 23 % of the patients had mild 
cognitive impairment (MCI), rising to 34 % after 1 year and 40 % after 3 years of 
follow-up. In the group with MCI at baseline 30 % had developed dementia after 6 
years of follow-up. In the group without MCI at baseline 30 % had developed 
dementia after 11 years of follow-up. No patients developed dementia the first year 
after surgery, corresponding to our observation. The rate of dementia development 
also corresponds to earlier studies [29, 31, 125, 126]. Neuropsychiatric symptoms in 
PD patients is a major cause of distress in caregivers, and dementia is a major 
contributor to disability and dependence in PD [127, 128]. As dementia develops in a 
large portion of STN-DBS treated patients similar to non-operated patients, it could 
support an approach of early surgery in eligible patients with PD in order to give the 
patients as many independent years as possible after surgery.  
Depression has been suggested to be an acute and perhaps indeed a chronic side effect 
after STN-DBS [1, 129-131]. This suggestion does not find support in our finding as 
depressive symptoms, as measured with MADRS, decreased from 9.1 on average 
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before surgery to 4.1 on average after surgery. The later development through follow-
up of clinical depression as defined by a MADRS score ≥ 15 was similar in operated 
and non-operated patients. Reports of depression being induced and perhaps 
maintained by stimulation seems to hail from the early, pioneering days of STN-DBS 
and may not be a notable challenge at the present. A possible explanation could be the 
shift in how dopaminergic medication is reduced postoperatively, as many centres in 
the beginning quickly withdrew all dopaminergic drugs as opposed to the modern 
approach where dopaminergic drugs are siphoned off in a more gradual fashion. 
Sudden withdrawal of dopaminergic medication is known to potentially induce or 
worsen non-motor symptoms in PD, including depressive symptoms [132]. 
Sleep disorders, apathy and hallucinations are all disabling symptoms associated with 
late stage PD. We found these symptoms to develop similarly in operated and non- 
operated patients, unaffected by STN-DBS. Again, this might support operating 
eligible PD patients earlier as they will presumably be able to enjoy more years of 
independent life. The EARLYSTIM study currently being conducted aims to explore 
the possible benefits of early intervention with STN-DBS [133].  
Fatigue, however, could be differently associated with STN-DBS than the other non-
motor symptoms we have examined. Fatigue has probably not been fully recognized in 
patients with PD. In community-based cross-sectional studies approximately 40 % of 
patients with PD report significant fatigue [134], with as much as a third of patients 
pointing at fatigue as the symptom most likely to limit them in activities of daily life. 
Our study 4 demonstrated a surprisingly high incidence of fatigue in patients treated 
with STN-DBS. 87 % of the SNT-DBS patients had clinical fatigue (FSS score ≥ 4) at 
final visit. 55 % of the patients in the reference population had clinical fatigue at the 
end of follow-up. The difference persisted after individual matching. After individual 
matching 91% of the operated patients had a FSS ≥ 4, compared to 67 % of the non-
operated patients. There has not been, as far as we know, any studies on long term 
development of fatigue after STN-DBS. A recent study found fatigue to be unchanged 
from preoperatively and until a 6 month follow-up after STN-DBS [135]. This 
corresponds well with our findings at 3-6 month follow-ups of STN-DBS patients. The 
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marked rise in fatigue in STN-DBS patients in our study appears between one year 
after surgery and the final visit. It is possible that our finding indicates a new and 
important long term side effect from STN-DBS treatment, but this would need further 
elucidation.  
 
Conclusion 
A central conclusion to be drawn on the basis of this thesis is that STN-DBS is a very 
good treatment option for motor symptoms in selected patients with advanced PD. 
Further, that the benefits of the treatment are limited to motor symptom control only, 
and that the underlying PD itself continues to develop in operated patients similar to 
the natural history of PD. The mechanisms by which STN-DBS mediates the 
beneficial effects on motor symptoms are still not fully understood. We have 
demonstrated acute improvements after STN-DBS not only on cardinal, dopaminergic 
motor symptoms [5, 6] but also on motor symptoms believed to be relatively 
independent of dopaminergic outflow, such as PIGD [7]. Further, STN-DBS treatment 
has its side effects and complications like all other treatments. The international 
literature reports wide variation of infection rates for STN-DBS, seemingly dependent 
on the definition of a postoperative infection. However, a general surgical 
complication rate of about 20 %, and an infection rate up to 15% seems to be valid 
figures [119, 136, 137]. Operative mortality has been reported internationally to be 
less than 2%, with many centres reporting no mortality at all [119, 136, 138].  
We have demonstrated in a large, Norwegian material that STN-DBS surgery can be 
performed with good and stable long time results on dopaminergic motor symptoms 
[5-7], with transient beneficial effects on PIGD symptoms, with low perioperative 
mortality [5] and with a low rate of major adverse events [5].  The non-motor features 
of PD develop independently of intervention with STN-DBS, as do FOG and falls. The 
thesis has also described possible long term side effects of STN-DBS not described 
earlier, as fatigue may seem to develop at a high rate in STN-DBS operated patients 
after the first year postoperatively [8]. The findings add new information relevant to 
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advising patients both about the indication for, and the timing of, STN-DBS surgery in 
PD. 
 
Future perspectives 
An increasing variety of leads, pulse generators and other hardware from a growing 
number of manufacturers are now available. This comes as a result of targeted R&D 
into DBS medical technology from several major companies in the med-tech sector. 
The physician and the individual patient have an increasing selection of implantable 
solutions to choose from, making it possible to make individual choices based on the 
needs and conditions of each PD patient. E.g. rechargeable and non-rechargeable pulse 
generators, and leads with different spacing have been available for some time.  
Recently, leads with the possibility of multiple independent current control have been 
introduced as a means to adjust the area of stimulation in the brain nuclei with even 
higher resolution. Innovative technical solutions now being tested and marketed 
include stimulation planning systems like the Boston Scientific GUIDE system. The 
system offers a 3D modelling tool to simulate the field of simulation in the individual 
patient taking into account the relative position of the electrodes in the individual 
patient in order to engineer precisely the brain area subjected to DBS. It is very likely 
that innovative improvements to the hardware and software utilized in DBS will 
continue to accelerate as demand for DBS procedures continue to grow. The number 
of patients eligible for an increasing variety of DBS treatments will likely grow, in 
concert with the coming demographic shift in many countries caused by ageing 
populations. Also for these reasons, we believe that STN-DBS will remain an 
important treatment option for selected patients with advanced PD for many years to 
come, despite developments in other novel treatments such as gene therapy and stem 
cell treatments. Our work supports STN-DBS as an effective, safe and long-term 
stabile treatment option with low mortality and low complication rates. We find no 
support for STN-DBS providing disease modulation or deceleration, and we argue that 
further research on STN-DBS should focus on improving patient selection and refining 
the treatment as such in order to further improve efficacy and reduce complication 
rates, perhaps reaching an international consensus on best practice. Much benefit for 
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STN-DBS patients could probably be gained if variance between centres in treatment 
efficacy and complication rates could be reduced and results across the institutions 
performing STN-DBS could be elevated to the level of the best centres internationally. 
Further, more knowledge on the effects of STN-DBS on a cellular and synaptic level is 
needed in order to fully understand the effects of the treatment on the PD effected 
brain. A full understanding of the mechanisms at the synaptic level could further refine 
the DBS procedures and promote even more innovative developments in DBS 
associated hardware and software. But it could also be of great value for exploring 
new pharmacological approaches to PD symptoms.  
Our studies serve to contribute in erasing the classical dogma of some motor 
symptoms being “dopaminergic” and some “non-dopaminergic”, or the notion of 
STN-DBS as being a purely “dopaminergic” treatment.  The range of effects by STN-
DBS on motor symptoms spans both categories. The possibility of development of 
severe fatigue as a side effect of STN-DBS in the long term requires further attention, 
both to clarify whether or not such a side effect really exists - and if so – how to 
reduce the impact on patients through selection and management of the therapy 
postoperatively. Exploring the mechanisms by which fatigue could be spawned by 
STN-DBS would also potentially bring new knowledge both on the physiological 
effects of STN-DBS, but perhaps also on the central nervous involvement in the 
development of fatigue. 
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ABSTRACT
Background: The objective of this study was to exam-
ine the clinical outcome and mortality of long-term
deep brain stimulation of the subthalamic nucleus in
advanced Parkinson’s disease.
Methods: We included all 144 patients (mean age,
60.3 years; mean disease duration, 11.0 years) treated
in our center from 2001 to 2007.
Results: Twelve months after surgery, the off-medica-
tion Uniﬁed Parkinson’s Disease Rating Scale motor
score was reduced by a mean of 53%, and the annual
increase after surgery was 3.2 points. The daily dose of
dopaminergic medication was reduced by a mean of
49% and increased only marginally during follow-up.
Twelve of the 144 patients died in the study period,
including 2 suicides (1.4%). Survival was 97% after 3
years and 90% after 5 years.
Conclusions: The study conﬁrms the stable efﬁcacy of
long-term subthalamic stimulation in selected patients
with advanced Parkinson’s disease. Throughout the
study the patient characteristics at time of surgery
changed, with less severe disease and shorter disease
duration toward the end of the study period. VC 2011
Movement Disorder Society
Key Words: deep brain stimulation; subthalamic nu-
cleus; mortality; suicide; survival; treatment outcome
Long-term medical management of Parkinson’s dis-
ease (PD) is frequently complicated by motor ﬂuctua-
tions and dyskinesias. Deep brain stimulation (DBS) of
the subthalamic nucleus (STN) is an effective treatment
in advanced PD, improving all cardinal motor symp-
toms and treatment-related motor complications.1,2 In a
randomized, controlled study of patients with severe
motor complications, STN-DBS was more effective than
best medical treatment.3 Short-term effects have been
reported in numerous case series.4 However, relatively
few studies have reported complete long-term data of
treatment efﬁcacy and mortality from single centers.
Here we report the ﬁndings of a retrospective study
of all patients receiving this treatment in our hospital
in a 7-year period from the ﬁrst procedure performed
in 2001, with complete analysis of survival. We also
show how our practice regarding patient selection has
evolved in the study period.
Patients and Methods
Patients
The ﬁrst 144 patients who received STN-DBS sur-
gery at Oslo University Hospital, from January 2001
to December 2007, were included in this retrospective
study. The criteria for STN-DBS were that the patients
had a diagnosis of PD, were younger than 75 years,
had levodopa-responsive motor symptoms with severe
motor complications and/or resting tremor with unsat-
isfactory levodopa response, and did not have demen-
tia or major psychiatric illness, marked cerebral
atrophy on MRI, or other contraindications to sur-
gery. Data were obtained from patient records. The
Regional Committee for Medical and Health Research
Ethics in South-East Norway approved the study.
Evaluation of Clinical Outcomes
Pre- and postoperative assessment included an inter-
view, neurological examination, and a levodopa-test
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comparing the UPDRS motor score in the off-medication
and on-medication states. Postoperative evaluation was
carried out 3 and 12 months after surgery and then
annually, with the neurostimulator turned on.
Preoperative levodopa response (difference between
preoperative UPDRS motor score in the off-medication
and on-medication states) and postoperative DBS
response (difference between UPDRS motor score off-
medication preoperatively and postoperatively on-
stimulation) were calculated. The primary outcome
variable was the ratio of postoperative response to
DBS and preoperative levodopa response. To study
changes in antiparkinsonian medication during STN-
DBS, the levodopa-equivalent daily dose (LEDD) was
calculated as previously published.3
Surgery was performed as described in the Support-
ing Information. Patients were followed until December
31, 2008, or death. The date of death was obtained
from the hospital’s electronic patient record system.
This system is continuously updated with information
from the National Population Register of Norway.
Statistical Analyses
Descriptive statistics were calculated for baseline
demographic and clinical data. Nonparametric tests
were used for 2-group and multiple-group compari-
sons. Missing postoperative UPDRS motor scores were
replaced by the score for the next performed assess-
ment. The possible association of various demographic
and disease- and treatment-related factors on treat-
ment efﬁcacy was ﬁrst explored using Mann–Whitney
U tests and Spearman Rank correlation coefﬁcients
and then studied with regression analyses.
Kaplan–Meier survival curves were constructed
using death (any cause) as the outcome. We examined
relationships between survival and patient characteris-
tics (sex, age, disease duration, preoperative LEDD,
and preoperative UPDRS motor score) using multivari-
ate Cox regression analysis. All statistical analyses
were performed using SPSS software version 16.0.
Results
Study Population
Ninety-three of the 144 patients were male (65%),
and 51 were female (35%). Mean (SD) age at surgery
was 60.3 (7.8) years, and disease duration was 11.0
(4.8) years. Nineteen of the 144 patients had previ-
ously been treated with stereotactic surgery. In this
group STN-DBS was initiated a median of 6 years
(range, 1–13 years) after the ﬁrst procedure. Preopera-
tive scores and at least 1 assessment 12 months after
surgery were available for 131 patients, and these
were included in the analyses of treatment effects.
Treatment Efﬁcacy
Mean postoperative follow-up was 3.3 years
(range, 1–7 years). UPDRS motor scores off- and on-
medication, LEDD, and stimulation parameters dur-
ing the course of the study are shown in Table 1.
Twelve months after surgery, the mean UPDRS
motor score off-medication was 18.4 with the stimu-
lator on, compared with a preoperative score of 39.0
(P < .001). The average improvement in UPDRS
motor scores due to STN-DBS was 53% (95% CI,
48%–57%), compared with a 67% (95% CI, 64%–
70%) average improvement due to preoperative levo-
dopa challenge. The mean LEDD was reduced by
49%, from 991 to 501 mg, in the same period (P <
.001) and increased only marginally during the post-
operative period. The mean annual increase of the
UPDRS motor score off-medication was 3.2 points
(Friedman test, P < .001).
The mean ratio of postoperative DBS response ver-
sus preoperative levodopa response was 0.80 (95%
CI, 0.71–0.89). As incomplete withdrawal of dopa-
mine agonists (DA) may affect the results of the pre-
operative levodopa test and 79 of the 131 patients
(60%) used a DA at the time of the preoperative
assessment, this ratio was also calculated separately
for DA users and non–DA users. The mean ratio for
Table 1. Motor scores, dopaminergic medication, and stimulation parameters during long-term STN-DBS treatment
Preoperative 12 months 24 months 36 months 48 months 60 months
Number of patients 131 131 110 89 52 32
UPDRS III Off 39.0 6 13.6 18.4 6 9.2 21.8 6 10.1 24.7 6 11.9 27.0 6 12.9 28.9 6 13.9
UPDRS III On 13.2 6 8.1 12.5 6 7.5 15.4 6 9.6 18.1 6 11.2 19.5 6 10.4 22.4 6 14.4
LEDD (mg) 991 6 462 501 6 285 539 6 334 536 6 369 517 6 349 525 6 331
Voltage left (V) NA 3.3 6 0.6 3.3 6 0.6 3.4 6 0.6 3.3 6 0.5 3.4 6 0.5
Voltage right (V) NA 3.1 6 0.6 3.3 6 0.7 3.4 6 0.6 3.4 6 0.6 3.3 6 0.6
Pulse width left (ls) NA 62 6 8 62 6 7 62 6 7 62 6 8 64 6 10
Pulse width right (ls) NA 61 6 6 61 6 8 62 6 8 61 6 4 64 6 10
Frequency (Hz) NA 158 6 22 160 6 27 166 6 16 170 6 17 173 6 17
Data presented are means 6 standard deviations of the patients examined at each time.
Abbreviations: LEDD, levodopa-equivalent daily dose; NA, not applicable; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
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the DA users was 0.71, compared with 0.93 in the
non–DA user group (P < 0.02).
The efﬁcacy of STN stimulation, measured by the ra-
tio of stimulation response versus levodopa response 12
months after surgery, correlated negatively with disease
duration and positively with preoperative UPDRS
motor scores, but both correlations were weak. We
found no association of treatment efﬁcacy with sex,
age, previous stereotactic procedures, preoperative
LEDD, the neurosurgeon performing the procedure, the
number of exploratory tracks, or year of surgery.
Changes in Patient Characteristics
The study group was divided in 3 groups depending
on the year of surgery (Fig. 1). The mean preoperative
UPDRS motor score was 45.2 among patients oper-
ated during the ﬁrst 2-year period and 35.3 in the last
2-year period. Mean disease duration before surgery
changed from 153 months in the ﬁrst period to 125
months in the last (P ¼ .09). There was no difference
in mean age at surgery during the study.
Mortality
The preoperative and postoperative mortality rates,
deﬁned as the number of deaths occurring during the
hospital stay or within the ﬁrst 30 days after discharge,
were 0. Twelve of the 144 patients died during the
study period (8.3%), with a median time from surgery
to death of 42 months (range, 3–77 months). Survival
was 97% after 3 years and 90% after 5 years (Fig. 2).
Two patients died within the ﬁrst 6 months of
causes probably related to the surgical treatment. In
addition, 2 of the 144 patients (1.4%) committed sui-
cide, 15 and 16 months after surgery. The remaining
8 of the 12 deceased patients died several years after
surgery, presumably of causes unrelated to the sur-
gery. Detailed description of these patients and of
severe adverse events are found in the Supporting
Information. Deceased and surviving patients were
compared for clinical characteristics. The mean age at
surgery of the deceased patients was 4 years higher
than that of the surviving patients (64.0 vs 60.0 years,
P ¼ .04; Supporting Fig. 1a). Deceased patients also
had more advanced disease at the time of surgery, with
a mean preoperative off-medication UPDRS motor
score of 52.0, compared with 38.3 in the surviving
patients (P ¼ .006, Supporting Fig. 1b). In the multi-
variate analysis, age and preoperative UPDRS motor
score were the only signiﬁcant prognostic factors.
Discussion
Our results support that long-term STN-DBS has a
stable effect on motor functions. The average annual
increase in off-medication UPDRS motor score was
3.2 points. This is very similar to the annual increase
of 3.3 points found in a previous population-based
study of PD from Norway,5 suggesting that an annual
increase of this size can be explained by natural dis-
ease progression. The stimulation parameters and the
dopaminergic treatment were increased only margin-
ally during the ﬁrst 60 months, further supporting the
stable long-term effect of the treatment.6
Our investigation was limited by the retrospective
nature of the study. However, the number of patients
was relatively large, and all patients receiving STN-
DBS in our center until the end of 2007 were included
consecutively and without exclusions.
We found a survival of 97% after 3 years and 90%
after 5 years. Very few previous studies have published
long-term survival data after STN-DBS. In a study by
Schu¨pbach and colleagues of 171 consecutive patients,
the calculated survival curve was almost identical to
our estimate.7 The only predictive factor for mortality
in their study was poorer cognitive function. We
found that age and more severe motor disability were
predictive factors. These results are not contradictory
FIG. 1. UPDRS motor scores off-medication during the course of
study. The study group was divided in 3 groups depending on the
year of surgery. The figure demonstrates the changes in the patients’
UPDRS motor scores off-medication during the study period. The
reduced preoperative UPDRS motor score between the 3 periods was
statistically significant (Kruskal-Wallis, P 5 .02).
FIG. 2. Kaplan–Meier curve of patient survival. The curve describes
survival probability over time. Vertical bars show patients who reached
end of follow-up alive.
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because age, cognitive function, and advanced motor
disability are factors related to mortality in PD.8
Wider and colleagues found a much higher mortality,
with a mean annual mortality ratio of 8.5%.9 How-
ever, this could be related to the higher age at surgery
of their patients.
Two of the 144 patients (1.4%) committed suicide.
Several previous studies have reported suicides after
STN-DBS.10,11 The suicide frequency has varied
between studies, but an international multicenter sur-
vey found a frequency of 0.45%.12 Despite the pres-
ence of a progressive disorder and frequent psychiatric
comorbidities, previous studies have not found higher
suicide rates in PD patients than in the general popula-
tion.13 This indicates that either subthalamic stimula-
tion increases the risk, or some of the patients
undergoing STN-DBS have increased suicide risk com-
pared with other PD patients. Both theories are sup-
ported by recent studies and are not mutually
exclusive. A cross-sectional study found increased
impulsivity scores in patients treated with STN-DBS
compared with patients receiving medical therapy.14
Several risk factors for attempted and completed suicide
after STN-DBS have also been identiﬁed, including
postoperative depression, being single, early disease
onset, and a history of impulse control disorders.12
There is an ongoing discussion regarding when in
the course of disease, surgery should be performed.
Patients who where operated on in the last part of our
study had lower preoperative UPDRS motor scores
than those operated on during the ﬁrst 2 years. There
are at least 2 probable explanations for this. First,
when STN-DBS surgery was established, some of the
most severely affected patients with long disease dura-
tion were probably among the ﬁrst to receive treat-
ment. The second explanation is that STN-DBS has
become a more accepted treatment and is considered
earlier now than some years ago. Results from
ongoing studies of STN-DBS earlier in the disease
course are awaited to provide further information on
the best time to perform surgery.
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Background – Treatment for Parkinson’s disease (PD) is symptomatic.
Surgical treatment with continuous high-frequency stimulation of the
subthalamic nucleus (STN-DBS) is established as a safe symptomatic
treatment with long-term beneﬁcial effects. It has been postulated that
STN-DBS could halt the progression of PD through a disease
modifying or neuroprotective effect. Objective – To investigate the
postulated disease modifying or neuroprotective effect of STN-DBS
by comparing the rate of deterioration of parkinsonism and mortality
over time in two selected and matched groups of patients with PD
with and without surgery. Methods – Group A was derived from all
patients who received STN-DSB surgery at Oslo University Hospital,
from January 2001 to December 2007. Group B was derived from a
prevalence study of PD in the Stavanger area of Western Norway in
1993. The two groups were individually matched and the disease
progression measured by Uniﬁed Parkinson’s Disease Rating Scale-
motor scores, and the mortality was compared. Results – The mean
annual change based on baseline and last observation scores in
individually matched groups was 0.97 (SD = 3.57) for the surgery
group and 1.04 (SD = 3.33) for the controls and thus not signiﬁcantly
different, F(1, 104) = .21, P = 0.89. The long-term mortality was also
similar in the two groups during long-term follow-up, hazard
ratio = 1.76, CL 0.91–3.40, P = 0.091. Conclusion – This study gives
no support to a postulated disease modifying or neuroprotective effect
of STN-DBS in patients with PD.
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Introduction
Parkinson’s disease (PD) is a progressive neurode-
generative disorder with great impact on patients,
their caregivers, and on the society in general (1).
Over the last decade, surgical treatment with con-
tinuous deep brain stimulation of the subthalamic
nucleus (STN-DBS) has been established as a safe
symptomatic treatment with long-term efﬁcacy
and acceptable complications (2–7).
Several recent papers have shown that the
motor effect of STN-DBS is long-lasting, but the
progression of parkinsonism continues (8–11).
However, it has also been postulated that
STN-DBS could have a disease modifying or
neuroprotective effect in PD and thus slow the
progression of the disease (1). It has been shown
that lesioning of the STN prevents degeneration of
the nigrostriatal dopaminergic pathways in the 6-
hydroxydopamine rat model (12–14). In addition,
it has been hypothesized that glutaminergic STN-
mediated neurotoxicity could be an etiological fac-
tor in the progressive decline of intact dopamine
neurons in the substantia nigra pars compacta and
that the reduction in the STN neuronal hyperac-
tivity by inhibition through high-frequency DBS
might slow or even halt the progression of neuron
degeneration in PD (15, 16).
This hypothesis has been examined by means
of serial 18F-ﬂurodopa positron emission
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tomography in 30 patients with successful STN-
DBS over the ﬁrst 16 months after surgery (17).
Hilker and co-workers demonstrated a continu-
ous decline of dopaminergic function in the range
of previously reported data from longitudinal
imaging studies in PD. They concluded that they
could not conﬁrm neuroprotective effects of high-
frequency DBS in the STN. Still, it is considered
a major unmet need in the understanding of
STN-DBS to further elucidate possible effects on
disease progression (1).
The aim of this study was therefore to examine
the possible inﬂuence of STN-DBS on motor pro-
gression by comparing the development of par-
kinsonism over time in a large longitudinal study
of patients with STN-DBS and in a population-
based long-term longitudinal study of only medi-
cally treated patients. In addition, we investigated
the rate of mortality in the two patient series to
examine the inﬂuence of the procedure on long-
term survival.
Material and methods
Patients
We have compared the rate of deterioration of
parkinsonism and mortality over time in two
selected and matched series of patients with PD.
Group A had performed STN-DBS surgery, and
group B was without surgery from the time per-
iod when such procedures were not routine treat-
ment for the disease.
Group A was derived from all patients who
received STN-DBS surgery at Oslo University
Hospital between January 2001 and December
2007. The inclusion criteria for surgery were a
clinical diagnosis of PD, age under 75 years, levo-
dopa-responsive motor symptoms with severe
motor complications, and/or resting tremor with
unsatisfactory levodopa response. Exclusion crite-
ria were dementia or major psychiatric illness,
marked cerebral atrophy on MRI, or other con-
traindications to surgery. This patient group was
followed annually from surgery until December
31, 2008 or until death. Data for this study were
obtained from patient records, as previously pub-
lished (8). The Regional Committee for Medical
and Health Research Ethics in southeast Norway
approved the study.
About 144 patients underwent STN-DBS.
Severe adverse events directly related to the sur-
gery occurred in 14 patients (10%). These
included ﬁve extracranial infections, ﬁve extracra-
nial hematomas, two seizures, one pulmonary
embolus, and one cerebral infarction. None of
the patients developed symptomatic intracranial
hemorrhages or intracranial infections. Further
details concerning these patients are previously
published (8).
Group B was derived from a prevalence study
of PD in the Stavanger area of Western Norway
on January 1, 1993. The crude prevalence rate
was 110.9 per 100,000 inhabitants (245 patients).
Patient recruitment was described previously in
detail (18). All patients were diagnosed by a neu-
rologist of the study group, according to pub-
lished diagnostic criteria (19). This patient group
was prospectively followed up with new examina-
tions 4 and 8 years after prevalence day (20, 21).
A subgroup of 22 deceased patients has been
assessed neuropathologically after they had given
written informed consent. In all subjects, cell loss
and synuclein-positive Lewy bodies were found in
the surviving neurons of substantia nigra, con-
ﬁrming the clinical diagnosis of PD (22). Tissue
processing and staining were performed following
standard protocols at the time (23).
Matching procedure
Group A, which comprised of patients who had
performed STN-DBS surgery, were selected from
the original 144 patients. We included in the
analyses patients who had been examined with
the motor part of the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS-motor) (24) in the medica-
tion ‘on’ state preoperatively, 3 months postoper-
atively, and at least at one more study visit giving
an observation period of at least 21 months.
UPDRS scoring was conducted in a standardized
setup in best ‘on’ state and performed by trained
physicians. Two patients died within the ﬁrst year
after the surgical procedure. Eleven patients were
either followed at other hospitals or preoperative
UPDRS scores could not be identiﬁed. Thirty-ﬁve
patients did not have a UPDRS part III score
3 months postoperatively and/or a repeated score
at a later study visit, and 15 patients had an
observation period of <21 months and were thus
excluded. Accordingly, 81 patients with a com-
plete data set were included in study group A.
Among the 245 patients from the population-
based control series, seven were re-diagnosed as
not having PD during follow-up, three patients
died between prevalence day and baseline exami-
nation, two patients refused to participate, and
one could not be evaluated due to severe demen-
tia. During the ﬁrst 4 years of follow-up, 81 had
died, one person had moved abroad, and six
patients refused participation in the examinations
in 1997. Thus, 144 patients had a least two
293
STN-DBS and progression of PD
observations of disease status and were eligible
for this study group B.
In the ﬁrst step of the matching procedure, we
excluded all patients from group B that at base-
line did not comply with the inclusion and exclu-
sion criteria for patients with surgery in group A.
This was age of 75 years or higher, dementia, or
major psychiatric illness. After application of the
exclusion criteria, 90 patients from group B
remained and had valid UPDRS-motor score
data at the 4-year examination.
Previous studies have shown that age is the
most important independent risk factor for a
more rapid progression of the UPDRS-motor
score (25, 26). Based on this, we performed a sec-
ond matching of the two patient groups. In this
matching, for each individual from group A was
sought an individual from group B with the same
age (3 years) at baseline. This ﬁnal matching
resulted in 54 patients in each patient series.
Demographic and clinical data
In both patient series, we collected data on age at
baseline of this study, gender, UPDRS-motor
scores in the stimulation ‘on’ and medication ‘on’
state, levodopa equivalent daily dose (LEDD)
(27), date of surgery, and date of death if this
occurred during the study period.
Data analysis
The matching of the two patient groups was based
on presurgical data in group A and data from
prevalence day (January 1, 1993) in group B. Dis-
ease progression as measured by UPDRS-motor
scores in the medication (and stimulation) ‘on’
state was calculated in group A with data from
3 months after surgery as baseline and with the
follow-up data from the visit closest to 45 months
after baseline (choosing the longest follow-up time
whenever there were similar follow-up times
around the 45-month follow-up). For group B,
calculations of progression are based on data from
prevalence day and until the 4-year follow-up visit.
Thus, for the patients with surgery, the preferred
UPDRS measurement point was at 45 months,
and for the controls, it was at 48 months. This
was carried out to have similar follow-up times in
the two groups, in case of nonlinear UPDRS
change with increasing follow-up time.
Disease progression is presented as mean
annual change in UPDRS-motor score based on
the average change from ﬁrst to last recorded
observations up to 4 years after baseline examin-
ations.
Differences in mean change in UPDRS-motor
score between groups A and B, according to both
matching criteria, were analyzed using analysis of
covariance (ANCOVA) with follow-up time, age,
and sex as covariates.
In addition to the evaluation of motor progres-
sion, we examined long-term survival in the two
patient groups during the observation period
from study start and until October 2011. We used
Cox regression to assess whether there were dif-
ferent hazard ratios (HRs) for operated versus
non-operated patients for death after baseline,
while controlling for sex and age at baseline.
Separate Cox regressions were performed for
complete groups and for groups after individual
matching.
Results
Patient group A comprised 81 patients that had
been treated with STN-DBS, and the control
group B included 90 patients after applying the
same inclusion and exclusion criteria as for the
operated patients. Table 1 shows demographic
and clinical characteristics of the two study
groups as well as mean annual progression of
UPDRS-motor score. The table also shows these
data after the ﬁnal individual matching according
to age at baseline with 54 patients in each group.
Progression of UPDRS-motor score over time
Table 1 shows the annual changes in UPDRS-
motor scores in groups A and B. These progres-
sion scores were not signiﬁcantly different when
controlling for follow-up time, age, and sex, nei-
ther in the matched groups, F(1, 103) = 1.68,
P = 0.199, nor the complete study groups,
F(1, 166) = 2.33 (P = 0.129). Further, to ensure
that the higher proportion of female patients in
the PD control group did not skew the analysis,
we conducted an analysis of variance (ANOVA)
in the complete study groups with sex and patient
group as ﬁxed factors and annual UPDRS
change as dependent variable. Sex did not affect
annual UPDRS change (P = 0.611), and there
was no interaction between sex and patient group
with regard to annual UPDRS change
(P = 0.201).
Long-term survival
In Fig. 1, the calculated survival curves are
shown for the complete study groups, based on
an observation time of 18 years for all the con-
trols and a mean observation time of 7.5 years
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on the operated group (SD 1.7). The Cox regres-
sion showed that age at baseline was a signiﬁcant
predictor of mortality, with a HR of 1.11, CL
1.07–1.15, P < 0.001. There was also a trend
toward a higher hazard rate for mortality for the
operated patients as opposed to the controls,
HR = 1.82, CL 0.99–3.32, P = 0.052. Age
represented a signiﬁcant hazard of mortality,
HR = 1.15, CL 1.09–1.22, P < 0.001. As in the
other matching condition, the STN-operated
patients showed a trend toward a higher risk of
death during the follow-up period, HR = 1.76,
CL 0.91–3.40, P = 0.091 [with an observation
time of 18 years for all the controls and a mean
observation time of 7.9 years on the operated
group (SD 1.7)].
Discussion
We found in this study that the rate of progres-
sion of parkinsonism and mortality was nearly
identical in a group of PD patients with deep
brain stimulation and in a historical control
group from the time period before widespread
use of STN-DBS. These ﬁndings were further
conﬁrmed when performing an individual match-
ing of the groups based on age of the patients at
baseline. The results from our study indicate that
Table 1 Clinical and demographic data of Parkinson’s disease (PD) patients with deep brain stimulation of the subthalamic nucleus (STN-DBS) and controls without
surgery in the study groups and after individual matching for age of the two patient groups
PD patients with STN-DBS PD control group patients
Study group Matched group Study group Matched group
No of patients 81 54 90 54
Mean age at baseline, years (SD) 61 (7) 64 (6) 66 (7) 64 (6)
% Females 35 39 52 57
Mean UPDRS follow-up measurement, month (SD) 38 (10) 39 (10) 48 (0) 48 (0)
Mean baseline UPDRS-III score (SD) 15 (8) 18 (9) 20 (11) 26 (13)
Mean baseline LEDD (SD) 448 (262) 433 (226) 537 (305) 581 (341)
Mean UPDRS-III progression pr year (SD) 1.16 (3.60) 1.15 (3.51) 1.43 (3.08) 1.04 (3.34)
LEDD, levodopa equivalent daily dose; UPDRS, Unified Parkinson’s Disease Rating Scale. UPDRS-III scores were measured in the medication and stimulation ‘on’ state.
Baseline data for the operated group were obtained 3 months after initiation of STN-DBS.
Figure 1. Cox regression curves showing calculated survival for deep brain stimulation of the subthalamic nucleus (STN-DBS)-
operated patients based on a mean observation time of 7.5 years and controls with an observation time of 18 years not individu-
ally matched for age. Age at baseline and sex were introduced in the calculations as covariates.
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STN-DBS treatment in patients with PD does
not inﬂuence the long-term progression of motor
impairment or patient survival. Our study may
thus bring an important contribution to the
controversy of a possible neuroprotective effect
of this procedure.
A potential neuroprotective effect of STN-DBS
has been primarily driven by a theoretical con-
cept related to an induction of reduced cytotoxic
glutamate release in substantia nigra by the pro-
cedure which again leads to less neurodegenera-
tion (15, 16). In addition, results from animal
studies have tended to support the neuroprotec-
tion hypothesis (12–14). In contrast, there are no
data from controlled patient studies that support
the validity of this concept and it has therefore
been seen as one of the important unanswered
research issues related to the STN-DBS proce-
dure (1). Although some studies have shown little
disease progression during the ﬁrst 2 years after
surgery (28), other long-term studies show that
the clinical syndrome gets worse over time (8–11).
In addition, a study using PET scans as outcome
measurement could not conﬁrm the experimental
data (17) and it has therefore been seen as neces-
sary to address this question through controlled
clinical studies. Such trials might, however, be
difﬁcult to design and run as the treatment proce-
dure today is established, and it would be consid-
ered as unethical to run a prospective randomised
controlled study over a sufﬁcient time period.
We have therefore in this study compared the
longitudinal development of severity of parkin-
sonism and mortality in two independent patient
cohorts. The operated patients received STN-
HFS surgery at Oslo University Hospital, from
January 2001 to December 2007, and were fol-
lowed from surgery until December 31 2008 or
until death. The control patients were derived
from a community-based group of prevalent cases
in Western Norway on January 1, 1993, that has
been followed up longitudinally (20, 21) for sev-
eral years. To ensure comparable patient groups,
we applied the same exclusion criteria for the
control group as for surgery.
The clinical picture and the rate of progression
show large heterogeneity in PD, and several stud-
ies have examined factors that can inﬂuence dis-
ease development. Although several factors are
associated with a more advanced disease stage,
only age at onset of disease (25) and age at base-
line of a study (29) are consistently found as
independent risk factors for a more severe
progression of parkinsonism. We have therefore
further matched the two patient groups by age to
overcome this problem. Also with these
somewhat smaller, but better matched groups,
the ﬁndings strongly indicate that the progression
is similar in patients with and without STN-DBS.
Parkinson’s disease is today recognized as a
multisystem brain disorder with a symptomatol-
ogy that comprises both motor and non-motor
symptoms, and measurements that intend to
reﬂect the cerebral progression of the disease are
controversial. The longitudinal development of
severity of parkinsonism, as measured with the
UPDRS-motor score in patients on optimal treat-
ment, is, however, considered as a valid assess-
ment for this (29, 30). Furthermore, we included
only patients with at least a 21-month observa-
tion period as the ﬁrst 6–12 months after surgery
may not be representative for the long-term
disease progression. The baseline time point for
calculating progression of parkinsonism was
3 months after the procedure to leave time for
adjustment of equipment and medication. Some
operated patients would therefore most probably
not be optimally treated at this evaluation leading
to an underestimation of the disease progression
in the surgery group, which further strengthens
the main ﬁnding of the study.
Although survival is not a direct measurement
of disease progression, it was anticipated that this
robust end point would give additional value to
the evaluation of the objective of this study. It
has previously been shown that patients with PD
have a moderately increased mortality rate (31),
and thus, a higher mortality in any of the study
groups would indicate that the disease process
would have developed more severely in those
patients. We found again no difference between
those with and without the STN-DBS treatment
when controlling for age and this further
strengthens the results related to the primary
outcome parameter.
There was small trend toward a higher risk of
death during the follow-up period in the STN-
DBS group. This could be the result of differ-
ences between the two groups despite individual
matching. The preoperative LEDD was higher in
the STN-DBS group than in the medication
group, indicating clinical differences that might
inﬂuence disease-related mortality.
In this study, we have compared disease pro-
gression in two different patient series which
made it necessary to use a historical control
group and to do post hoc matching of the
included patients. This study design has several
obvious shortcomings compared with the wanted
randomized blinded prospective trial. We still
believe that this approach is as close as it is possi-
ble to come to run a head-to-head comparison of
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progression of parkinsonism and mortality in
patients with and without STN-DBS.
The study has other important shortcomings as
well. The rather low number of patients and the
lack of a blinded and randomized control group
could have given a biased picture of disease
development both in the short- and long-term
perspective. Also, the need to include only
patients with sufﬁcient data constitutes a risk of
selection bias. In particular, the comparison of
the matched groups was carried out based on
small samples. The small sample size makes it
more difﬁcult to demonstrate any differences
between the two groups by statistical analysis.
Another weakness of this study is that to include
patients with data from long-time follow-up, only
patients still alive at the end of the 6- to 9-year
observation period have been included, as
opposed to patients who died during follow-up.
Data on disease duration before baseline were
not available for Group A. Not analyzing this
variable could add to the risk of selection bias.
However, our results are in line with the newer
long-term observational studies carried out on
operated patients (9, 10). The results from this
study should therefore be valid and fairly robust,
despite the above-mentioned shortcomings. Our
study together with other recent studies (9, 10)
thus strongly argues against a neuroprotective
effect of the STN-DBS. Still it is clear that the
symptomatic effect of this treatment is well estab-
lished, and it thus represents an important treat-
ment option in the management of PD.
In conclusion, our study gave no support to
the postulated disease modifying or neuroprotec-
tive effect of STN-DBS. We found no signiﬁcant
difference between the surgery and non-surgery
groups in the mean annual change in UPDRS-
motor score, nor in mortality. The absence of sig-
niﬁcant differences was upheld when controlling
for age by individual matching. These ﬁndings
strongly contradict a neuroprotective or disease
modifying effect of STN-DBS. Thus, further
research in the ﬁeld of surgical treatment for PD
with STN-DBS may better focus on reﬁning the
method and on obtaining even better symptom
control, rather than pursuing an alleged disease
modifying effect that seems not to exist.
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Objectives – Stimulation of the subthalamic nucleus (STN-DBS) is an
established treatment with long-term beneﬁcial effects on motor
symptoms in patients with Parkinson’s disease (PD). The efﬁcacy of
STN-DBS on non-dopaminergic motor symptoms remains less
elucidated. In this study, we have examined short- and long-term
impacts of STN-DBS on the development of the postural instability
and gait difﬁculties (PIGD) phenotype, freezing of gait (FOG), and
falls. Materials and methods – We collected data from a prospectively
followed cohort of patients that had been operated with STN-DBS
6–9 years before ﬁnal examination and compared our ﬁndings to the
longitudinal development of the same symptoms in a non-operated,
historical reference population. Results – During short-term follow-up
after surgery, we observed a marked improvement in mean UPDRS-
motor score from 27 to 18. We also found clear improvements in
tremor, bradykinesia, rigidity, and PIGD scores. However, 6–9 years
after surgery, all patients had a dominating PIGD pattern of
parkinsonism and 50% of the patients had developed FOG and/or
had become recurrent fallers. The disease development in a group of
patients with PD from the presurgery period had a similar trajectory
as among the operated patients. In addition, mean annual change of
both bradykinesia and PIGD scores was nearly identical in both study
groups while tremor and rigidity had a signiﬁcant better development
in the operated patients. Conclusions – We found that STN-DBS
induces an acute improvement of PIGD symptoms. The following
long-term development was however characterized by a marked
progression of non-dopaminergic symptoms.
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Introduction
Deep brain stimulation of the subthalamic
nucleus (STN-DBS) is established as an effective
and safe treatment option in patients with
Parkinson’s disease (PD) suffering from motor
complications with dopaminergic therapy (1, 2).
STN-DBS is documented to have a stabilizing
effect on the severity of parkinsonism that seems
to be preserved for many years after surgery (1,
3). Still, the procedure’s impact on the so-called
non-dopaminergic motor problems is not sufﬁ-
ciently clear (1, 4).
Motor symptoms that have poor or no
response to dopaminergic treatment include axial
motor involvement leading to postural instability
and gait difﬁculties (PIGD) (5, 6), freezing of gait
(FOG), and falls. These symptoms are substan-
tially disabling and reduce quality of life in
patients and caregivers (7–9). The frequency of
these symptoms increases as PD develops in the
brain with an increasing number of dispersed
lesions (10). In addition, the PIGD pattern of
parkinsonism is associated with a faster rate of
cognitive decline and increased risk for subse-
quent dementia (10, 11).
The pathophysiology of PIGD, FOG, and falls
are poorly understood and is probably complex.
Still, brainstem and midbrain locomotor areas
are thought to play a major role in the control of
balance and gait (10) and also deﬁcits in cognitive
functions may inﬂuence the development of these
1
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dominating axial symptoms of PD. On the other
hand, the depletion of the dopaminergic system is
considered to be less important. If this is true,
STN-DBS would be expected to have a limited
impact on such symptoms after surgery. But the
effects of STN-DBS are not yet clear. A meta-
analysis of several long-term studies on bilateral
DBS in the STN and the internal globus pallidus
internus (GPi) did, however, indicate that the pro-
cedures can have acute effects on PIGD (12). It is
still assumed from clinical experience that the
effects may be small, and in addition, these symp-
toms would be expected to progress at the same
rate as observed in non-operated patients with PD.
We wished to elucidate these issues, and the
aims of our study were to examine the short- and
long-term impact of STN-DBS on the develop-
ment of the PIGD phenotype, FOG, and falls in
a prospectively followed cohort of patients with
PD that had been operated 6–9 years before ﬁnal
examination. Furthermore, we have compared
these ﬁndings to the longitudinal development of
the same symptoms in a non-operated, historical
reference population.
Materials and methods
In this study, we have examined prospectively
until 2012 the development of parkinsonism,
PIGD, FOG, and falling over time in a group of
patients with PD who received STN-DBS surgery
at Stavanger University Hospital between July 1,
2003 and June 30, 2006. The Regional Committee
for Medical and Health Research Ethics in Wes-
tern Norway approved the study.
The inclusion criteria for surgery in this study
were a clinical diagnosis of PD, a positive levo-
dopa challenging test, dyskinesias unresponsive to
medical treatment and on/off complications.
Exclusion criteria were dementia or major psychi-
atric illness in the patient’s history, marked cere-
bral atrophy on MRI, age >75 years, or other
common contraindications to surgery. A total of
28 patients with PD received STN-DBS implants.
Sixteen of them were still alive in 2012 and had
sufﬁcient clinical data to be included in this
study. Of those excluded, ﬁve patients had died
2–6 years after surgery, three did not agree to
participate in the follow-up, and in four patients,
the device was no longer functioning. The DBS
surgery was conducted according to the proce-
dure used by the National Hospital in Oslo, Nor-
way as previously published (3), with an initial
improvement in motor function. Trajectories were
planned with the target in the dorsolateral, moto-
ric part of the STN bilaterally.
To obtain information on the expected natural
history of these symptoms, we have also exam-
ined the longitudinal development of parkinson-
ism, PIGD, FOG, and falls in a comparable
group of patients from the time period when
STN-DBS were not routine treatment for PD.
This group of patients was derived from a preva-
lence study of PD in the Stavanger area of Wes-
tern Norway on January 1, 1993. The crude
prevalence rate was 110.9 per 100,000 inhabitants
(245 patients). Patient recruitment has been
described in detail previously (13). All patients
were diagnosed by a neurologist of the study
group, according to published diagnostic criteria
(14).
Among the 245 patients from this cohort, seven
were re-diagnosed as not having PD during fol-
low-up, three patients died between prevalence
day and baseline examination, two patients
refused to participate, and one could not be eval-
uated due to severe dementia. During the ﬁrst
4 years of follow-up, 81 had died, one person
had moved abroad, and six patients refused par-
ticipation in the examinations in 1997. Between
1997 and 2001, further 55 patients had died and
thus 89 patients completed the 8-year follow-up
and were eligible for evaluation in this study.
Among these 89, we ﬁrst excluded patients
according to the same exclusion criteria used for
patients evaluated for surgery. This was age of
75 years or higher, dementia, or major psychiatric
illness. After application of the exclusion criteria,
62 patients remained. In addition, we did an indi-
vidual matching of patients in the two groups
based on several factors at baseline of the study
that could inﬂuence the future disease symptoms
relevant for this study. The statistical approach
and factors included in this matching are
described in the Statistics section. This ﬁnal indi-
vidual matching resulted in two groups of 12
patients that could be compared for long-term
development of parkinsonism, PIGD, FOG, and
falls.
Examination program
All patients with STN-DBS surgery were exam-
ined preoperatively and 3–6 months postopera-
tively to evaluate the short-term effects on
parkinsonism, PIGD, FOG, and falls. In addi-
tion, these patients were examined 1 year after
implantation and again in a long-term follow-up
during 2011 and 2012. This examination took
place 6–9 years after surgery. Patients in the ref-
erence group were prospectively followed up with
new examinations 4 and 8 years after baseline
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(15, 16). All examinations were performed in best
‘ON’ and with stimulator on, if present.
The examinations performed at each study visit
included a semi-structured interview on disease
history and drug treatment [the levodopa-equiva-
lent levodopa dose (LEDD) was calculated in mg
(17)], the Uniﬁed Parkinson Disease Rating Scale
(UPDRS) (18) and Hoehn and Yahr stage (19).
Measures of tremor, rigidity, bradykinesia, and
PIGD were derived from the UPDRS activity of
daily living (ADL) and motor sections. We calcu-
lated sum scores and mean per UPDRS item
scores for tremor (items 16, 20–21), PIGD symp-
toms (items 13–15, 29–30), bradykinesia (items
23–26, 31), and rigidity (item 22). Based on the
relative severity of tremor vs PIGD symptoms
(mean of UPDRS items 13–15, 29–30), motor
phenotype was determined as either tremor domi-
nant (TD) or postural instability/gait difﬁculty
(PIGD) phenotype (patients with indeterminate
type were classiﬁed as non-PIGD), following the
classiﬁcation algorithm proposed by Jankovic
et al. (20). FOG was deﬁned as a score of >1 on
the UPDRS part II item 14 (freezing when walk-
ing), which was measured on a 0 (normal) to 4
(severe) scale. The cut-off was selected to elimi-
nate false positives. Falls were deﬁned as a score
of >1 on the UPDRS part II item 13 (falling not
caused by freezing), thus primarily targeting
recurrent fallers.
Data analyses and statistics
In this study, we examined the short-term effects
of STN-DBS by comparing clinical features
before and 3–6 months after surgery. The long-
term development of symptoms is described in
the STN-DBS patients with the clinical status
3–6 months after surgery as the baseline observa-
tion and until last observation. Disease develop-
ment in the reference cohort was calculated from
baseline and until 8-year follow-up.
All statistical analysis was performed in SPSS
version 20 IBM N.Y., USA. Descriptive statistics
for continuous data are presented as means and
standard deviations (SDs) and for categorical
data as counts and percentages. Conﬁdence inter-
vals (CIs) for means are based on the normal
approximation. Observed scores for the STN-
operated patients are compared to those of the
controls using independent samples t-tests.
The STN-operated patients were, based on
their 3–6 months postoperative scores, individu-
ally matched to comparable controls by means of
propensity scores matching (21). The matching
routine took into consideration gender (22), being
over 67 years of age (yes/no), LEDD, mean
UPDRS tremor and PIGD scores, PIGD type
(yes/no), total UPDRS-motor score, total UP-
DRS ADL score, and the interaction between
LEDD and all other covariates. The covariates
were centered and rescaled as appropriate before
being entered into a logistic regression model
with outcome STN operated (yes/no). The pre-
dicted probabilities or propensities of being in the
STN-operated group were then used for individu-
ally matching the STN-operated to non-operated
controls deemed eligible for operation, by apply-
ing a ‘greedy’ nearest neighbor matching routine
based in the SPSS syntax posted online by John
S. Painter (23). Due to non-overlapping propen-
sity scores distributions (24), the four of the oper-
ated with highest propensity scores were
discarded from the matched groups.
Results
Table 1 shows demographic and clinical data for
patients with and without STN-DBS. Data are
shown before and after surgery for the operated
patients (n = 16) and at baseline for the non-
operated patients (n = 62) with PD. Also data for
the two individually matched groups (n = 12 in
both groups) are shown. The mean age for the
operated patients was 60 years and with 80%
PIGD dominating pattern of parkinsonism. Two
patients had FOG and three were recurrent fal-
lers. The non-surgery group was older and had
less severe parkinsonism and fewer patients with
FOG and falls. After matching, the groups were
more similar.
PIGD, FOG, and falls during short-term follow-up
Table 1 also shows the clinical characteristics
before and after surgery for the patients that had
received STN-DBS implants. We observed a
marked improvement in mean UPDRS-motor
score from 27 to 18. We also found clear
improvements in tremor, bradykinesia, rigidity,
and PIGD scores. Only one patient was changed
from dominating PIGD to tremor dominant par-
kinsonism. In addition, the two patients with
FOG before surgery, no longer reported this
complaint. One of three patients who were recur-
rent fallers before surgery reported improvement.
PIGD, FOG, and falls during long-term follow-up
Table 2 shows the mean PIGD score and propor-
tion of patients with PIGD pattern of parkinson-
ism, FOG, and falls at baseline (3–6 months after
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surgery), at 1 year after surgery and at ﬁnal visit
in 2012 for patients with STN-DBS and the same
ﬁndings for patients in the control cohort at base-
line and after 8-year follow-up. The table also
shows the ﬁndings in the individually matched
cohorts. Among the operated patients, the mean
PIGD sum score increased from 2.5 at baseline
to 4.2 after 1 year and after 6–9 years to 9.7
(Table 2). At baseline 75% had dominating
PIGD, but at ﬁnal visit all patients had devel-
oped this disease pattern. No patients had FOG,
and two were fallers at baseline. This was
unchanged after 1 year while about 50% of the
patients had these manifestations at ﬁnal visit.
The development of PIGD score, and proportion
with PIGD dominance were nearly identical in
Table 1 Demographic and clinical data for patients with and without STN-DBS. Data are shown before and after surgery for the operated patients and at baseline for
the non-operated patients with PD. Also data for the matched groups are shown. The results are given as mean (SD), unless stated otherwise
STN-DBS operated,
preoperatively, n = 16
STN-DBS operated,
after surgery, n = 16
Reference population,
baseline, n = 62
Matched STN-DBS operated,
after surgery, n = 12
Matched from the reference
population, n = 12
Age, years 60 (8.1) 60 (8.4) 66 (6.7) 61 (8.0) 61 (8.3)
LEDD, mg 960 (220) 740 (380) 520 (250) 740 (290) 720 (220)
UPDRS-II total score 11 (10)* 7.2 (5.1) 8.7 (4.5) 7.8 (5.0) 7.3 (4.0)
UPDRS-III total score 27 (13) 18 (7.5) 18 (10) 17 (6.4) 16 (8.4)
Hoehn and Yahr stage 2.5 (0.6)* 2.1 (0.6)* 2.2 (0.8) 2.1 (0.7) 2.0 (0.7)
Tremor score 3.2 (4.1)* 2.6 (4.1) 4.3 (3.8) 2.3 (3.3) 2.7 (4.5)
Bradykinesia score 12 (7.3) 8.7 (4.5) 8.5 (5.6) 8.0 (4.3) 7.3 (4.4)
Rigidity score 6.1 (3.1) 3.1 (2.6) 2.2 (1.8) 2.5 (2.4) 2.4 (1.9)
PIGD score 3.9 (2.1)* 2.5 (2.0) 2.6 (2.2) 2.8 (2.3) 2.3 (1.9)
PIGD dominance (%) 13 (81)* 12 (75) 28 (45) 9 (75) 8 (67)
FOG (%) 2 (13)* 0 (0) 3 (5) 0 (0) 0 (0)
Falls (%) 3 (20)* 2 (13) 1 (2) 2 (17) 1 (8)
*Based on 15 patients, values missing for one patient.
Table 2 Mean PIGD score and proportion of patients with PIGD pattern of parkinsonism, FOG, and falls at baseline (3–6 months after surgery), at 1 year after surgery
and at final visit in 2012 (long-term follow-up) for patients with STN-DBS and the same findings for patients in the control cohort at baseline and after 8-year follow-up.
Also data for the matched groups are shown. Results are given as mean (SD), unless stated otherwise
STN-DBS operated (n = 16)
Eligible for surgery from
reference population (n = 62)
STN-DBS operated
matched (n = 12)
Reference population,
matched (n = 12)
Baseline visit
LEDD, mg 740 (380) 520 (250) 740 (290) 720 (220)
Tremor score 2.6 (4.1) 4.3 (3.8) 2.3 (3.3) 2.7 (4.5)
Bradykinesia score 8.7 (4.5) 8.5 (5.6) 8.0 (4.3) 7.3 (4.4)
Rigidity score 3.1 (2.6) 2.2 (1.8) 2.5 (2.4) 2.4 (1.9)
PIGD score 2.5 (2.0) 2.6 (2.2) 2.8 (2.3) 2.3 (1.9)
PIGD type (%) 12 (75) 28 (45) 9 (75) 8 (67)
FOG (%) 0 (0) 3 (5) 0 (0) 0 (0)
Falls (%) 2 (13) 1 (2) 2 (17) 1 (8)
1-Year visit
LEDD, mg 840 (470) 830 (250)
Tremor score 1.6 (2.3) 1.8 (2.6)
Bradykinesia score 10 (5.1) 9.7 (4.7)
Rigidity score 4.3 (3.9) 3.6 (2.9)
PIGD score 4.2 (2.3) 4.3 (2.5)
PIGD type (%) 14 (88) 10 (83)
FOG (%) 0 (0) 0 (0)
Falls (%) 2 (13) 1 (8)
Long-term follow-up
LEDD (mg) 910 (320) 700 (430) 870 (330) 1010 (320)
Tremor score 0.7 (1.3) 6.1 (5.3) 0.6 (1.0) 4.4 (3.9)
Bradykinesia score 19 (5.6) 20 (9.2) 19 (5.5) 15 (6.0)
Rigidity score 3.4 (4.4) 5.8 (4.5) 2.5 (3.7) 3.7 (3.7)
PIGD score 9.7 (5.1) 9.4 (5.5) 10 (5.3) 7.4 (3.4)
PIGD type (%) 16 (100) 52 (84) 12 (100) 10 (83)
FOG (%) 9 (56) 31 (50) 7 (58) 7 (58)
Falls (%) 8 (50) 31 (50) 6 (50) 5 (42)
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the historical control group, both seen as a whole
group and in the individually matched cohorts.
Table 3 shows the mean annual change in
mean score per item of PIGD, tremor, bradykine-
sia and rigidity in the study period. The mean
annual change of PIGD was 0.19 for patients
with STN-DBS. The development for the refer-
ence population of patients with PD was similar.
For tremor and rigidity, there was a small mean
annual reduction in scores among the operated
patients and a signiﬁcantly different increase in
the control group. Bradykinesia increased at a
similar rate in both groups over time.
Discussion
This study shows that STN-DBS induces an acute
improvement of PIGD symptoms as measured
3–6 months after surgery. The further disease
development is, however, characterized by a
marked long-term deterioration of these symp-
toms. Six to nine years after surgery, all patients
had a dominating PIGD pattern of parkinsonism.
In addition, 50% of the patients had developed
FOG and had become recurrent fallers. For refer-
ence, we also examined the disease development
in a group of patients from the presurgery period
and found that the progression of these dominat-
ing non-dopaminergic symptoms had a similar
trajectory as among the operated patients with
PD. In addition, mean annual change of both
bradykinesia and PIGD scores was nearly identi-
cal in both study groups during long-term follow-
up, while tremor and rigidity had a signiﬁcant
better development in the operated patients. Our
ﬁndings indicate that STN-DBS improves PIGD
symptoms initially, but the further development
of these symptoms and FOG and falls seems not
to be inﬂuenced by persistent stimulation.
Deep brain stimulation of the subthalamic
nucleus has ever since its advent delivered impres-
sive results on motor symptoms in PD, improving
the level of functioning and quality of life in
severely disabled patients with PD. But from
reports (12) on long-term follow-up after
STN-DBS, it has been increasingly clear that this
therapy, although very successful in reducing
severe PD symptoms, has its limitations on non-
dopaminergic aspects of PD. Our study has inves-
tigated one possible shortcoming of STN-DBS –
its potential lack of effect on motor symptoms
not primarily related to the dopaminergic system.
It has been postulated that PD is a disease with
several clinical subtypes with variable expressions
(20), and thus maybe with different response to
STN-DBS. Disability also varies due to the clini-
cal pattern of PD, with the PIGD subtype caus-
ing more disability than, for example, tremor
dominant PD (20).
Our ﬁndings both conﬁrm and extend on the
results from a recent meta-analysis of these issues
(12). This analysis included 11 studies with
UPDRS scores before and beyond 3 years post-
surgery (mean 4.5 years). Random effects meta-
regression revealed that DBS initially improved
PIGD compared to before surgery, but perfor-
mance progressively declined over time and
PIGD was worse than presurgery function within
2 years for patients with STN-DBS. These ﬁnd-
ings are in line with our results. We found that
the PIGD sum score decreased from 3.9 to 2.5
after surgery, but with an increase to 4.2 after
1 year and 9.7 after 6–9 years post-surgery, and
the frequency of FOG and falls during long-term
follow-up was markedly increased. Furthermore,
we have examined the development of PIGD,
FOG, and falls in a reference population from
the presurgery era and observed a similar rate of
progression of these primarily non-dopaminergic
symptoms as among the patients with STN-DBS.
Taken together, our results and previous studies
support an acute effect on PIGD symptoms by
STN-DBS but with a marked deterioration of
these symptoms and frequency of FOG and fall-
ing over time.
There has been a long-standing agreement that
stereotactic procedures in the thalami have no
effect on non-dopaminergic motor symptoms
(25). In contrast, it remains uncertain whether
DBS in the STN or GPi truly inﬂuence these
Table 3 Mean annual change in mean PIGD, tremor, bradykinesia, and rigidity scores, as measured by the UPDRS
STN-DBS operated (n = 16)
Mean 95% CI
Eligible for surgery from
reference population (n = 62)
Mean 95% CI P*
STN-DBS operated,
matched (n = 12)
Mean 95% CI
Reference population,
matched (n = 12)
Mean 95% CI P*
PIGD mean score (range 0–4) 0.19 (0.13–0.24) 0.17 (0.14–0.20) 0.639 0.19 (0.12–0.26) 0.13 (0.09–0.17) 0.095
Tremor mean score (range 0–4) 0.03 (0.07 to 0.01) 0.03 (0.01–0.42) 0.002 0.03 (0.07 to 0.01) 0.02 (0.03 to 0.08) 0.087
Bradykinesia mean score (range 0–4) 0.14 (0.10–0.19) 0.16 (0.14–0.19) 0.496 0.15 (0.09–0.21) 0.11 (0.06–0.15) 0.204
Rigidity mean score (range 0–4) 0.00 (0.06 to 0.05) 0.09 (0.06–0.12) 0.002 0.01 (0.05 to 0.04) 0.03 (0.02 to 0.09) 0.280
*From independent samples t-tests.
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symptoms, even though previous studies provide
some support (12, 26, 27). The results are far from
clear, with the best indications as to some effect on
non-dopaminergic motor symptoms related to
GPi-DBS in combination with levodopa (12). In
this study, we found a rather substantial improve-
ment during the ﬁrst months after STN-DBS on
PIGD score. The observed initial improvement of
presumed non-dopaminergic motor symptoms
after surgery could have different explanations. It
could be caused by effects of STN-DBS outside the
dopaminergic system, or the fact that the actual
PIGD score (which includes items like walking and
gait) may be inﬂuenced by increased dopaminergic
stimulation and accompanying improvement of
general motor function. In addition, a placebo
effect related to being treated with surgery might
have been responsible for this initial improvement.
The results from this study seem not to contribute
to the discussions on STN-DBS as a pure dopami-
nergic treatment or PIGD as pure non-dopaminer-
gic symptoms.
When counseling and advising patients prior to
DBS surgery, it is important to inform the
patients about beneﬁts as well as limitations of
surgical treatment. STN-DBS has proven to be a
successful therapy for dopaminergic motor symp-
toms in PD, but non-dopaminergic features of
PD can be just as, or even more so, disabling and
detrimental to the patient’s and the caretaker’s
quality of life. Our study adds to the evidence
that STN-DBS does not prevent, nor alleviates,
the long-term development of non-dopaminergic
motor symptoms in PD. This should be taken
into the total consideration, and may affect the
indication for surgery – especially if a patient
already has noticeable non-dopaminergic motor
symptoms, or such symptoms contributes signiﬁ-
cantly to the patients total burden of disease. In
addition, in the meta-analysis (12) discussed
above it was shown that DBS-GPi in combina-
tion with levodopa seemed to preserve PIGD bet-
ter than DBS-STN during long-term follow-up,
although more studies of DBS-GPi and random-
ized controls were considered necessary.
The study design applied in this study has several
important shortcomings. The rather low number
of patients and the lack of a blinded and random-
ized control group could have given a biased pic-
ture of disease development both in the short- and
long-term perspective. In particular, the compari-
son of the matched groups was made based on
small samples. The small sample size makes it more
difﬁcult to demonstrate any differences between
the two groups by statistical analysis. Another
weakness of this study is that to include patients
with data from long time follow-up, only patients
still alive at the end of the 6–9 year observation
period have been included, as opposed to patients
who died during follow-up. Also, the introduction
of new treatment possibilities over the intervening
decade between the recruitment of the two study
groups could affect disease progression and the
drug treatment administered to the patients. This
could affect the calculated LEDD (17) for the
patients of the two groups, but should not affect
the observations of changes in LEDD for the indi-
vidual patient.
Still, our ﬁndings seem in line with previous
studies on important outcomes like the scores on
cardinal signs of PD. We have also made an
attempt to include comparative information on
how the expected disease development would be in
a group of patients without surgery and especially
the patients in the individually matched reference
group would most probably have been offered sur-
gery if that had been an option at the time. We
therefore believe that the results must be regarded
as fairly robust despite these shortcomings.
In conclusion, we have found that patients with
STN-DBS have acute beneﬁcial effects on PIGD
symptoms, but continue to progress thereafter at
a similar rate as the general PD population. This
information is important when informing patients
and may also have consequences for the choice of
surgical targets in the individual patients. Still,
there is a need for more information on the
impact of surgery on PIGD, FOG, and falls by
alternative targets.
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Objectives – Stimulation of the subthalamic nucleus (STN-DBS) is an
established treatment with long-term beneﬁcial effects on motor
symptoms in patients with Parkinson’s disease (PD). The long-term
development of non-motor problems after STN-DBS is not fully
understood. In this study, we have studied how non-motor problems
develop in patients with and without STN-DBS. Materials and
methods – We collected data from a prospectively followed cohort of
patients that had been operated with STN-DBS 6–9 years before ﬁnal
examination and compared our ﬁndings to the longitudinal
development of non-motor problems in a non-operated, comparable
reference population. Results – In general, the non-motor problems of
advanced PD seem to develop independently of treatment with STN-
DBS. We found that depressions do not worsen after STN-DBS, and
the Montgomery and Aasberg Depression Rating Scale score in
operated patients was substantially reduced from pre-operatively to
post-operatively. Further, fatigue may represent an important
unrecognized side effect of long-term stimulation, as fatigue was
found to increase rapidly in operated patients already a year after
surgery and continued to increase trough the 6- to 9-year follow-up.
Conclusions – The non-motor problems of advanced PD seem to
develop independently of treatment with STN-DBS. This may
inﬂuence the strategy for choice of when to perform this therapy for
eligible patients.
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Introduction
Deep brain stimulation of the subthalamic nuclei
(STN-DBS) is an effective treatment option in
patients with advanced Parkinson’s disease (PD)
(1). Data from recent long-term studies indicate a
persistent effect of stimulation on the cardinal
motor symptoms of the disease (1–3). However,
the disability of the PD patients deteriorates over
time, and this seems caused by both an increase
in severity of parkinsonism and the progression
of non-motor problems (4–7).
The non-motor symptoms progressing and
incapacitating the patients include cognitive
impairment, neuropsychiatric symptoms, sleep
problems, and autonomic symptoms. The symp-
toms are thought to primarily develop as the
pathology of PD involves non-dopaminergic
structures in the brain, and disease progression
should be anticipated to develop independently
from the STN-DBS procedure. In addition, the
implantation of the stimulation electrode itself
could potentially have short- or long-term effects
on cerebral systems that may impact these non-
motor functions both beneﬁcially and negatively.
Cognitive impairment and dementia are major
contributing factors for decreased functioning in
patients with late-stage PD (4, 5). In a study that
followed 14 patients with STN-DBS for more
than 9 years, it was found that four of them
developed dementia (8), and in another study,
one of 20 patients became demented (9). In gen-
eral, the risk for developing dementia is up to six-
fold higher in PD than in non-PD subjects and
about 10% of patients with PD develop dementia
per year (10, 11). The incidence of dementia
increases with age (12), and as patients with
STN-DBS usually are younger than the general
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PD population, several aspects of the relationship
between STN-DBS and dementia need further
exploration.
In addition, a number of other non-motor
problems are likely to develop in patients with
STN-DBS. We have therefore, in this study, pro-
spectively examined the development of dementia
and several other important non-motor problems
during long-term follow-up of patients with
STN-DBS and compared these ﬁndings with the
longitudinal development of such problems in a
non-operated historical reference population.
Material and methods
Study design
In this study, we have examined prospectively,
until 2012, the development of cognitive impair-
ment and dementia, sleep problems, apathy,
depression, fatigue, and hallucinations over time
in a group of patients with PD who received
STN-DBS surgery at Stavanger University Hospi-
tal between July 1, 2003 and June 30, 2006. We
have studied these symptoms prospectively both
before and after surgery and during long-term
follow-up. The patients were examined before
surgery, 3–6 months and 1 year after surgery,
and at the ﬁnal follow-up visit 6–9 years after
implantation. In addition, we have compared the
observed progression of non-motor symptoms
with that of a historical reference population of
patients with PD. The reference population was
made up by patients eligible for STN-DBS from
a prevalence study (13), in which the patients
were followed prospectively from 1993 to 2001,
that is, in the time period before STN-DBS
became a routine treatment option. The operated
patients and the reference population were two
independent cohorts from two consecutive dec-
ades, but both cohorts had prospective follow-up
and largely overlapping examination programs at
study visits. The Regional Committee for Medical
and Health Research Ethics in Western Norway
approved the study.
Patients
Twenty-eight patients with PD received STN-DBS
implants during the inclusion period. In 2012, at
follow-up, 16 patients were still alive and had suf-
ﬁcient clinical data to be included in this study.
Five patients had died, and three did not agree to
participate in the follow-up. In four patients, the
device was not functioning, and for these four
patients, no follow-up data were available.
The inclusion criteria for surgery in this study
were a clinical diagnosis of PD, dyskinesias unre-
sponsive to medical treatment, and on/off compli-
cations. Exclusion criteria were dementia or
major psychiatric illness in the patient’s history,
marked cerebral atrophy on MRI,
age > 75 years, or other common contraindica-
tions to surgery.
The DBS surgery was conducted according to
the procedure used by the National Hospital in
Oslo, Norway, as previously published (2). Tra-
jectories were planned with the target in the dor-
solateral, motoric part of the STN bilaterally.
In addition to the patients with STN-DBS, we
established a reference population of patients that
was derived from a prevalence study of PD in the
Stavanger area of Western Norway on January 1,
1993. The crude prevalence rate was 110.9 per
100,000 inhabitants (245 patients). Patients were
recruited through a search in the patient records
at the hospital covering the region, with letters to
all general practitioners in the study area and
through cooperation with the local Parkinson
Association. The prevalence study and the
recruitment of the population have been
described in detail previously (13). All patients
were diagnosed by a neurologist of the study
group, according to published diagnostic criteria
(14). Among the 245 patients from this cohort,
seven were rediagnosed as not having PD during
follow-up, three patients died between prevalence
day and baseline examination, two patients
refused to participate, and one could not be eval-
uated due to severe dementia. During the ﬁrst
4 years of follow-up, 81 had died, one person
had moved abroad, and six patients refused to
participate in the examinations in 1997. Between
1997 and 2001, further 55 patients had died, and
thus, 89 patients completed the 8-year follow-up
and were eligible for evaluation in this study.
Among these 89, we ﬁrst excluded patients
according to the same exclusion criteria as used
for patients evaluated for surgery. This was age
above 75 years, dementia, or major psychiatric
illness. After application of the exclusion criteria,
62 patients remained eligible for the study and
could thus in principle have been candidates for
surgery. Patients in the reference group were pro-
spectively followed up with new examinations 4
and 8 years after baseline (15, 16). In addition,
we did an individual matching of patients in the
two groups based on several factors at baseline of
the studies to obtain a reference cohort of
patients that would have had a high probability
to be candidates for surgery if this had been an
option at the time. The statistical approach and
252
Lilleeng et al.
factors included in this matching are described in
the Statistics section. This ﬁnal individual match-
ing resulted in two groups of 12 patients that
could be compared for development of non-
motor symptoms (Table 3).
Examination program
The examination performed at each study visit
included a semistructured interview on disease
history, drug treatment [the levodopa-equivalent
levodopa dose (LEDD)] was calculated in mg
(17), the Uniﬁed Parkinson Disease Rating Scale
(UPDRS) (18), and Hoehn and Yahr stage (19).
Cognitive functions were tested using Mini-
Mental State Examination (MMSE) (20), and
dementia was diagnosed according to the Diag-
nostic and Statistical Manual of Mental Disor-
ders, Third Edition, Revised, DSM-III-R (21).
Hypersomnia was examined with the Epworth
Sleepiness Scale (ESS) (22). In addition, informa-
tion on excessive daytime sleepiness (EDS),
insomnia, and proportion of patients with at least
moderately difﬁculties during the night were
available at study end for both operated patients
and patients with PD in the reference population.
EDS was diagnosed in patients falling asleep at
least three times or who were sleeping 2 h or
more during daytime.
Apathy was assessed with the 14-item Stark-
stein Apathy Scale (SAS) (23). SAS scores were
not available at baseline in the reference popula-
tion. In addition, the percentage of patients and
controls with apathy were deﬁned with a score of
2 or more on the motivation/initiative item (item
4) of the UPDRS.
Depression was measured with the Montgom-
ery and Aasberg Depression Rating Scale (MAD-
RS) (24), and we present mean scores and
proportion of patients with MADRS score above
14 as a suggested cutoff to deﬁne a valid measure
of major depression (25).
Fatigue was assessed with the Fatigue Severity
Scale (FSS) (26), and we calculated both the
mean group FSS scores and the percentage of
patients with a FSS score ≥ 4 as a measure of
having clinical fatigue.
Information on the presence of hallucinations
was derived from the UPDRS-I subscore, item 2
(thought disorder). Patients with a score of 2 or
more were deﬁned as having hallucinations.
Statistics
All statistical analysis was performed in SPSS ver-
sion 20, IBM Corporation Armonk, New York,
United States. Descriptive statistics for continu-
ous data are presented as means and standard
deviations (SDs) and for categorical data as
counts and percentages. Proportions were com-
pared between time points within groups using
McNemar’s test and between groups using the
chi-squared test.
The STN-operated patients were, based on
their 3–6 months post-operative scores, individu-
ally matched to comparable controls by means of
propensity scores matching (27, 28). Based on the
gender, being over 67 years of age (yes/no),
LEDD, mean UPDRS tremor scores, mean UP-
DRS PIGD scores, PIGD type (yes/no), total
UPDRS motor score, and total UPDRS ADL
score, each patient’s probability or propensity of
being STN operated was estimated and used for
matching. Due to non-overlapping propensity
score distributions (29), the four of the operated
with highest propensity scores were discarded,
thus giving matched groups of 12 to be com-
pared. Further details regarding the matching
process have been previously published (30).
Results
Tables 1 and 2 show the demographic and clini-
cal features of patients with (n = 16) and without
(n = 62) STN-DBS. Data from the operated
patients are shown before and 3–6 months,
1 year, and 6–9 years after surgery. Data from
the reference population are presented at baseline
and at 8-year follow-up. Data for the two indi-
vidually matched groups (n = 12 in both groups)
are shown in Table 3.
Among the 16 patients included in the study,
ﬁve (31%) patients had developed dementia at
last visit 6–9 years after surgery according to the
DSM-III-R criteria. All ﬁve developed dementia
between 1 year after surgery and ﬁnal visit.
Among patients in the reference population, 46%
had developed dementia. The MMSE scores
changed from 28.4 at 3–6 months after surgery to
23.4 at ﬁnal visit in the STN-DBS group and
from 28.3 to 22.6 in the reference population
(Tables 1 and 2). In the individually matched
groups, the results were comparable (Table 3)
Hypersomnia was not a major problem among
the operated patients as measured with ESS,
although slowly increasing with age as expected.
There was also a similar frequency of EDS and
insomnia among the STN-DBS patients as in the
reference population. Comparable ﬁndings were
present for apathy (Tables 1–3).
Mean MADRS score was 9.1 before and 4.1 at
3–6 months after operation. Major depression
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was found in two before and none patients 3–
6 months after implantation (Table 1). During
follow-up, the severity of depressive symptoms
was rather stable and comparable to the observa-
tions in the reference group (Tables 2 and 3).
Fatigue before surgery and after surgery was
unchanged as measured with mean FSS score and
proportion of patients with a score of 4 or more
on this scale (Table 1). Surprisingly, these mea-
sures showed a clear deterioration during follow-
up (last visit vs 3–6 months after surgery
(P = 0.008), and as compared to the reference
patients at ﬁnal visit (P = 0.025). At the ﬁnal
visit, 87% of the patients with STN-DBS had a
mean FSS score of 4 or above. Only 55% of the
patients from the reference population had clini-
cal fatigue after 8 years of follow-up (Table 2).
In the matched groups, the percentage of oper-
ated patients with FSS of 4 or above also
increased notably from 45% at baseline, to 75%
after a year and peaked at 91% at the ﬁnal visit.
The percentage of patients in the matched non-
operated group with FSS at or above 4 upon the
ﬁnal visit was 67%. Thus, the comparison of the
matched groups also demonstrated a difference in
the frequency of fatigue at the ﬁnal visit.
Four of the patients with STN-DBS reported
hallucinations before surgery but none 3–6 months
after (Table 1). During follow-up, 50% of the
patients in the surgery group had hallucinations
as compared to 37% in the reference population
(Table 2). After the matching, this difference
disappeared, with 50% of the patients experienc-
ing hallucinations in both groups at the ﬁnal
visit.
Discussion
This study shows that PD patients with STN-
DBS have a rather stable long-term motor
function, but a substantial proportion of them
develop dementia and cognitive impairment dur-
ing follow-up. Further, we have in this study
examined the short- and long-term progression of
several non-motor problems among operated
patients and found that these problems develop
in general as in non-operated patients with PD.
Fatigue was, however, found to increase over
time more than expected and depressive symp-
toms were markedly improved by initiation of
STN-DBS. Our results underscore that the surgi-
cal procedure is a treatment of motor symptoms
Table 1 Demographic and clinical data for PD patients with and without STN-DBS. Data are shown before and 3–6 months after surgery for the operated patients
(n = 16) and at baseline for the non-operated patients, that is, the reference population (n = 62). Furthermore, data are given for individually matched subgroups of the
two patients groups (n = 12). The results are given as means (SDs) unless otherwise stated. For scores with missing observations, the numbers of available observations
are indicated
STN-DBS operated,
pre-operatively
(n = 16)
STN-DBS operated,
post-surgery
(n = 16)
STN-DBS operated,
matched, post-surgery
(n = 12)
Reference group,
baseline
(n = 62)
Reference group,
matched, baseline
(n = 12)
Age (years) 60 (8.1) 60 (8.4) 61 (8.0) 66 (6.7) 61 (8.3)
Female gender, no. (%) 10 (63%) 10 (63%) 8 (67%) 33 (53%) 8 (67%)
Disease duration (years) 12.9 (5.7) (n = 14) 13.3 (5.6) (n = 15) 12.5 (5.1) (n = 11) 7.7 (4.9) 10.6 (4.9)
LEDD (mg) 960 (220) 740 (380) 740 (290) 520 (250) 720 (220)
UPDRS-II total 11 (10) (n = 15) 7.2 (5.1) 7.8 (5.0) 8.7 (4.5) 7.3 (4.0)
UPDRS-III total 27 (13) 18 (7.5) 16.8 (6.4) 18 (10) 15.8 (8.4)
Hoehn and Yahr stage 2.5 (0.6) (n = 15) 2.1 (0.6) (n = 15) 2.1 (0.7) (n = 11) 2.2 (0.8) 2.0 (0.7)
MMSE 29.1 (1.6) (n = 15) 28.4 (3.0) (n = 15) 28.2 (3.3) 28.3 (1.8) 28.7 (2.1)
Dementia, no. (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ESS 6.5 (4.3) (n = 12) 6.3 (4.3) (n = 13) 6.8 (4.8) (n = 10) NA NA
EDS, no. (%) NA NA NA 2 (3%) 0 (0%)
Difficult night, no. (%) NA NA NA 10 (16%) 1 (8%)
Insomnia, no. (%) NA NA NA 37 (60%) 9 (75%)
Apathy scale 14.7 (4.1) (n = 12) 16.9 (5.2) (n = 14) 18.0 (4.7) (n = 11) NA NA
Item 4 UPDRS-I 0.9 (1.3) 0.3 (0.5) 0.3 (0.5) 0.8 (0.8) 0.7 (0.9)
Item 4 UPDRS-I ≥ 2, no. (%) 3 (19%) 0 (0%) 0 (0%) 13 (21%) 3 (25%)
MADRS 9.1 (9.1) (n = 10) 4.1 (3.0) (n = 14) 4.4 (3.1) (n = 11) 5.6 (4.2) 5.4 (3.7)
MADRS ≥ 15, no. (%) 2 (20%) (n = 10) 0 (0%) (n = 14) 0 (0%) (n = 11) 3 (5%) 0 (0%)
FSS mean 4.1 (1.7) (n = 11) 3.7 (1.7) (n = 14) 4.1 (1.7) (n = 11) NA NA
FSS ≥ 4, no. (%) 5 (46%) (n = 11) 5 (36%) (n = 14) 5 (42%) (n = 11) NA NA
Item 2 UPDRS-I 0.69 (0.87) 0.7 (0.9) 0.1 (0.3) 0.42 (0.69) 0.3 (0.5)
Item 2 UPDRS-I ≥ 2, no. (%) 4 (25%) 3 (25%) 0 (0%) 3 (5%) 0 (0%)
STN-DBS, deep brain stimulation of the subthalamic nuclei; LEDD, levodopa-equivalent levodopa dose; UPDRS, Unified Parkinson Disease Rating Scale; MMSE, Mini-Mental
State Examination; ESS, Epworth Sleepiness Scale; EDS, excessive daytime sleepiness; MADRS, Montgomery and Aasberg Depression Rating Scale; FSS, Fatigue Severity
Scale.
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and that the non-motor problems will cause
important impairments as the disease develops
also for these patients. These ﬁndings may indi-
cate that optimal beneﬁts from STN-DBS are
achieved when treating younger patients and by
starting earlier when motor problems dominate.
Patients with PD may experience a multitude
of different non-motor symptoms as the disease
progresses (4, 5). This study has examined the
development of several important such symptoms
among patients with STN-DBS in both short-
and long-term follow-up. In accordance with pre-
vious reports (10, 11, 16, 31), we found that ﬁve
of 16 patients became demented 6–9 years after
surgery and with a mean MMSE score of 23.4 at
last study visit. The development of cognitive
impairment in the reference population from the
presurgery era showed similar or even stronger
deterioration. These patients were, however,
6 years older at baseline. The development of
cognitive impairment that has an important inﬂu-
ence on the life of patient and caregiver and
health costs seems not improved by this surgical
procedure.
Sleep problems that include insomnia, hyper-
somnia, and sleep-related symptoms are impor-
tant complaints in especially late-stage PD (4, 5).
The patients in this study also developed these
symptoms. Apathy and hallucinations developed
to a similar extent both in patients with STN-
DBS and patients from the reference population.
Depression has been reported as an acute and
even chronic side effect of STN-DBS (1, 32–34).
In this study, we observed a marked improve-
ment in depressive symptoms with a mean MAD-
RS score of 9.1 before and 4.1 after surgery. The
MADRS score was varying and similar during
follow-up among both the STN-DBS and the ref-
erence patients. These ﬁndings indicate that previ-
ous warnings related to depression and even
suicide were primarily based on observations in
the early, establishing phase of STN-DBS ther-
apy.
Fatigue is an under-recognized symptom in
patients with PD. Previous studies have, however,
shown that in community-based cross-sectional
populations about 40% of patients with PD have
signiﬁcant fatigue (35), and one-third of the
patients report fatigue to be the symptom most
likely to limit their daily life activities (35). In this
study, we found surprisingly that 87% of the
patients with STN-DBS had fatigue at ﬁnal visit
compared to 55% in the reference population,
and already 1 year after surgery, 67% had a FSS
score at ≥ 4. The difference was seen also after
matching, with the percentages of patients with a
FSS score ≥ 4 at 91% and 67% at the ﬁnal visit
in the operated and non-operated groups, respec-
Table 2 Long-term development of non-motor symptoms for PD patients with and without STN-DBS. Data are collected 3–6 months, 1–1.5 years, and 6–9 years after
surgery for the operated patients (n = 16), and at baseline and after 8 years for the non-operated patients (n = 62). The results are given as means (SDs) unless
otherwise stated. For scores with missing observations, the numbers of available observations are indicated
STN-DBS operated,
3–6 months post-surgery
(n = 16)
STN-DBS operated,
1–1.5 years after surgery
(n = 16)
STN-DBS operated,
6–9 years after surgery (n = 16)
Reference population,
baseline
(n = 62)
Reference population,
8 years after baseline
(n = 62)
LEDD (mg) 740 (380) 810 (510) 910 (320) 520 (250) 700 (430)
UPDRS-II total 7.2 (5.1) 9.6 (5.4) 20 (7.3) 8.7 (4.5) 23 (10)
UPDRS-III total 18 (7.5) 22 (10) 33 (12) 18 (10) 43 (20)
Hoehn and Yahr stage 2.1 (0.6) (n = 15) 2.1 (0.5) (n = 14) 3.2 (0.9) 2.2 (0.8) 3.2 (1.0)
MMSE 28.4 (3.0) (n = 15) 28.4 (2.7) (n = 14) 23.4 (8.0) 28.3 (1.8) 22.6 (8.0) (n = 58)
Dementia, no. (%) 0 (0%) 0 (0%) 5 (31%) 0 (0%) 28 (45%)
ESS 6.3 (4.3) (n = 13) 7.5 (3.7) (n = 11) 10.1 (7.0) NA 9.6 (6.6)
EDS, no. (%) NA NA 2 (13%) (n = 15) 2 (3%) 26 (42%)
Difficult night, no. (%) NA NA 2 (13%) (n = 15) 10 (16%) 10 (16%)
Insomnia, no. (%) NA NA 5 (33%) (n = 15) 37 (60%) 32 (52%)
Apathy scale 16.9 (5.2) (n = 14) 16.3 (5.9) (n = 13) 19.3 (4.4) (n = 15) NA 15.1 (3.3) (n = 47)
Item 4 UPDRS-I 0.3 (0.5) 0.8 (0.9) 1.5 (1.2) 0.8 (0.8) 1.4 (1.1)
Item 4 UPDRS-I ≥ 2, no. (%) 0 (0%) 3 (19%) 7 (44%) 13 (21%) 25 (40%)
MADRS 4.1 (3.0) (n = 14) 6.8 (5.5) (n = 15) 5.0 (6.0) 5.6 (4.2) 7.4 (6.2) (n = 42)
MADRS ≥ 15, no. (%) 0 (0%) (n = 14) 2 (13%) (n = 15) 1 (6%) 3 (5%) 6 (14%) (n = 42)
FSS mean 3.7 (1.7) (n = 14) 4.6 (1.5) (n = 15) 5.0 (1.6) (n = 15) NA 4.4 (1.8) (n = 58)
FSS ≥ 4, no. (%) 5 (36%) (n = 14) 10 (67%) (n = 15) 13 (87%) (n = 15) NA 32 (55%) (n = 58)
Item 2 UPDRS-I 0.19 (0.40) 0.50 (0.73) 1.4 (1.2) 0.42 (0.69) 1.2 (1.1)
Item 2 UPDRS-I ≥ 2, no. (%) 0 (0%) 2 (13%) 8 (50%) 3 (5%) 23 (37%)
STN-DBS, deep brain stimulation of the subthalamic nuclei; LEDD, levodopa-equivalent levodopa dose; UPDRS, Unified Parkinson Disease Rating Scale; MMSE, Mini-Mental
State Examination; ESS, Epworth Sleepiness Scale; EDS, excessive daytime sleepiness; MADRS, Montgomery and Aasberg Depression Rating Scale; FSS, Fatigue Severity
Scale.
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tively. To our knowledge, fatigue has not previ-
ously been examined in long-term follow-up of
patients with STN-DBS. In a recent study, fati-
gue was found to be unchanged from before and
till 6 months after surgery (36) in line with our
ﬁndings 3–6 months after implantation. Our
observation of a marked increase of fatigue over
time may thus represent a new important side
effect during follow-up of patients with STN-
DBS that warrants further exploration.
Taken together, the results from this study
show that patients with STN-DBS develop the
same pattern of incapacitating non-motor symp-
toms as in the general PD population. This may
have implications for the evaluation of which
patients are the most suitable for such therapy.
Higher age and duration of disease are the two
most important factors that drive the appearance
of non-motor problems in PD and as these prob-
lems develop in patients with advanced disease,
motor problems become less important for level
of functioning and quality of life. In consequence,
the beneﬁts from STN-DBS are thus highest in
patients with low age at disease onset and in the
earlier disease stages. The ﬁndings from this
study therefore support the concept of neurosti-
mulation at an earlier stage of PD than previ-
ously advocated. This is also being investigated in
the EARLYSTIM study (37).
This study has several important shortcomings.
A rather low number of patients and that we only
included patients that were still alive and with a
functioning STN-DBS device at the end of the 6–
9 years observation period may challenge the rep-
resentativeness of our ﬁndings. In addition, we
did not have a blinded and randomized control
group, and at some study visits, we had missing
data or only data – especially for sleep problems –
at the ﬁnal follow-up visit. This could have given
an incomplete or biased picture of disease devel-
opment both in the short- and long-term perspec-
tive and with the small sample size making it
more difﬁcult to demonstrate any differences
between the groups by statistical analysis. The
individually matched groups of operated and non-
operated patients could have increased the possi-
bility of uncovering signiﬁcant differences. We
did, however, not ﬁnd any further differences in
the long-term development of clinical symptoms
when comparing the matched groups. Further-
more, several factors besides the effects of STN-
DBS like a possible placebo effect or changes in
the dopamine replacement therapy could inﬂuence
the outcome (38, 39). Reduction in dopamine
therapy could induce improvement in non-motor
side effects of the drugs or, in some cases, lead to
a dopamine agonist withdrawal syndrome with
worsening of non-motor problems (40).
Table 3 Long-term development of non-motor symptoms for PD patients with STN-DBS and for individually matched PD patients without STN-DBS. Data are collected 3–
6 months, 1–1.5 years, and 6–9 years after surgery for the operated patients (n = 12), and at baseline and after 8 years for the non-operated patients (n = 12). The
results are given as means (SDs) unless otherwise stated. For scores with missing observations, the numbers of available observations are indicated
STN-DBS operated,
3–6 months post-surgery
(n = 12)
STN-DBS operated,
1–1.5 years after surgery
(n = 12)
STN-DBS operated,
6–9 years after surgery
(n = 12)
Reference population,
baseline
(n = 12)
Reference population,
8 years after baseline
(n = 12)
LEDD (mg) 740 (290) 830 (250) 870 (330) 720 (220) 1000 (320)
UPDRS-II total 7.8 (5.0) 9.8 (5.3) 20.6 (7.8) 7.3 (4.0) 20.5 (5.9)
UPDRS-III total 16.8 (6.4) 20.4 (9.0) 32.8 (11.1) 15.8 (8.4) 30.3 (11.7)
Hoehn and Yahr stage 2.1 (0.7) (n = 11) 2.2 (0.4) (n = 10) 3.3 (0.9) 2.0 (0.7) 2.8 (0.4)
MMSE 28.2 (3.3) 28.4 (2.8) 23.3 (8.9) 28.7 (2.1) 23.7 (6.4)
Dementia, no. (%) 0 (0%) 0 (0%) 4 (33%) 0 (0%) 6 (50%)
ESS 6.8 (4.8) (n = 10) 8.3 (3.4) (n = 9) 10.3 (7.3) NA 7.3 (5.3)
EDS, no. (%) NA NA 2 (18%) (n = 11) 0 (0%) 5 (42%)
Difficult night, no. (%) NA NA 2 (18%) (n = 11) 1 (8%) 2 (17%)
Insomnia, no. (%) NA NA 4 (36%) (n = 11) 9 (75%) 5 (42%)
Apathy scale 18.0 (4.7) (n = 11) 17.9 (4.8) (n = 10) 18.5 (3.4) (n = 11) NA 14.1 (2.7) (n = 11)
Item 4 UPDRS-I 0.3 (0.5) 0.8 (1.0) 1.6 (1.2) 0.7 (0.9) 1.1 (0.9)
Item 4 UPDRS-I ≥ 2, no. (%) 0 (0%) 2 (17%) 6 (50%) 3 (25%) 5 (42%)
MADRS 4.4 (3.1) (n = 11) 7.4 (5.9) 5.3 (6.9) 5.4 (3.7) 7.7 (4.8) (n = 10)
MADRS ≥ 15, no. (%) 0 (0%) (n = 11) 2 (17%) 1 (8%) 0 (0%) 2 (20%) (n = 10)
FSS mean 4.1 (1.7) (n = 11) 5.0 (1.4) 5.2 (1.3) (n = 11) NA 4.6 (2.0)
FSS ≥ 4, no. (%) 5 (45%) (n = 11) 9 (75%) 10 (91%) (n = 11) NA 8 (67%)
Item 2 UPDRS-I 0.1 (0.3) 0.5 (0.7) 1.5 (1.2) 0.3 (0.5) 1.5 (1.0)
Item 2 UPDRS-I ≥ 2, no. (%) 0 (0%) 1 (8%) 6 (50%) 0 (0%) 6 (50%)
STN-DBS, deep brain stimulation of the subthalamic nuclei; LEDD, levodopa-equivalent levodopa dose; UPDRS, Unified Parkinson Disease Rating Scale; MMSE, Mini-Mental
State Examination; ESS, Epworth Sleepiness Scale; EDS, excessive daytime sleepiness; MADRS, Montgomery and Aasberg Depression Rating Scale; FSS, Fatigue Severity
Scale.
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Still, the observed results on motor function
are in line with previous reports, and we have
also made an attempt to include information on
how the disease was expected to develop in a ref-
erence population of patients with PD without
surgery. We therefore believe that the results may
be important and valid despite these shortcom-
ings. Another strength of our study is the wide
range of the examined non-motor problems that
also resulted in an observation of fatigue as a
possible important side effect in long-term fol-
low-up of patients with STN-DBS.
We have in this study examined the long-term
development of speciﬁc non-motor symptoms
after STN-DBS. In addition, it could have been
important to study the development of the holis-
tic impact of non-motor problems on the lives of
patients with PD (41) that have been operated
with STN-DBS. The use of instruments like the
non-motor symptoms scale (42) could have added
to the value of this study.
In conclusion, we have in this study found that
in general the non-motor problems of advanced
PD develop independently of treatment with
STN-DBS. This may inﬂuence the strategy for
choice of when to perform this therapy in the dis-
ease development of the individual patient. In
addition, we found importantly that depression
do not worsen after STN-DBS but improves
mood substantially after surgery. Furthermore,
fatigue may represent an important unrecognized
side effect of long-term stimulation.
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